var title_f33_18_34080="Abscess cavity";
var content_f33_18_34080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anaerobic pulmonary abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, thick-walled cavity in the right middle lobe due to an anaerobic pulmonary abscess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34080=[""].join("\n");
var outline_f33_18_34080=null;
var title_f33_18_34081="Elevated PD pressure manometry";
var content_f33_18_34081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80705%7EGAST%2F57715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80705%7EGAST%2F57715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Sphincter of Oddi manometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of elevated basal sphincter of Oddi (SO) pressure in the pancreatic segment (PD) of the SO.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Walter J Hogan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Sphincter of Oddi manometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 167px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of elevated basal sphincter of Oddi (SO) pressure and a pressure gradient between the pancreatic duct and duodenum obtained during manometric catheter pull-through of the pancreatic segment of the SO.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Walter J Hogan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34081=[""].join("\n");
var outline_f33_18_34081=null;
var title_f33_18_34082="Attapulgite: Drug information";
var content_f33_18_34082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Attapulgite: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/55/11122?source=see_link\">",
"    see \"Attapulgite: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kaopectate&reg; Children&rsquo;s [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiarrheal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Diarrhea:",
"     </b>",
"     Oral (give after each bowel movement): 1200-1500 mg/dose; maximum dose: 8400 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/55/11122?source=see_link\">",
"      see \"Attapulgite: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Diarrhea:",
"     </b>",
"     Oral (give after each bowel movement):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-6 years: 300 mg/dose; maximum dose: 2100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 600-750 mg/dose; maximum dose: 4500 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg;: 600 mg/15 mL (250 mL, 350 mL) [vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg; Children&rsquo;s: 600 mg/15 mL (180 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg; Extra Strength: 750 mg/15 mL (250 mL, 350 mL) [peppermint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2638186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake liquid well before administering. Do not administer within 2-3 hours of other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of diarrhea and cramps",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kaopectate&reg; may be confused with Kayexalate&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       <b>",
"        Note:",
"       </b>",
"       Attapulgite preparations have been discontinued in the U.S.; refer to Bismuth monograph for newly-reformulated Kaopectate&reg; products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to attapulgite or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5695536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consult healthcare provider before initiating therapy if high fever or bloody stools are present. Do not use for &gt;2 days. If diarrhea persists, consult healthcare provider. Dosage not established in children &lt;3 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2638188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Signs of fluid and electrolyte loss",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F138008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actapulgite (BE, CH, FR);",
"     </li>",
"     <li>",
"      Kaopectate (PL);",
"     </li>",
"     <li>",
"      New Diatabs (ID);",
"     </li>",
"     <li>",
"      Polymagma (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nonselectively absorbs excess intestinal fluid, thereby reducing stool liquidity. May interfere with absorption of nutrients and other drugs as well.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Not absorbed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Engle JP, &ldquo;Antidiarrheal Products,&rdquo;",
"      <i>",
"       American Druggist",
"      </i>",
"      , August 1994:48, 50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ericsson CD, &ldquo;Nonantimicrobial Agents in the Prevention and Treatment of Traveler&rsquo;s Diarrhea,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(Suppl 8):557-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34082/abstract-text/16267719/pubmed\" id=\"16267719\" target=\"_blank\">",
"        16267719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forrester A, &ldquo;Diarrhea,&rdquo;",
"      <i>",
"       Patient Self-Care (PSC)",
"      </i>",
"      , Canadian Pharmacists Association, 2002: 238-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horne JS and Swanson LN, &ldquo;Diarrhea,&rdquo;",
"      <i>",
"       U.S. Pharm",
"      </i>",
"      , May 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim-Jung L, Holquist C, and Phillips J, &ldquo;Kaopectate Reformulation and Upcoming Labeling Changes,&rdquo;",
"      <i>",
"       Drug Topics",
"      </i>",
"      , 2004, April 19:58-60.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9261 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34082=[""].join("\n");
var outline_f33_18_34082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138012\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138023\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138014\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138019\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138015\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950024\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217267\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638186\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138004\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138027\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138007\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5695536\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137997\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638188\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138008\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137993\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138006\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9261\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9261|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/55/11122?source=related_link\">",
"      Attapulgite: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_18_34083="Early events Tcell transduction";
var content_f33_18_34083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Early events in T cell receptor signal transduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After antigen binds the TCR, Lck is activated and phosphorylates tryosine residues within the ITAMs of the CD3 and &zeta; chains, allowing ZAP-70 to be recruited to the TCR. Once ZAP-70 binds the phosphorylated ITAMs, it is phosphorylated by Lck, triggering all downstream signaling events required for T-cell activation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kane, LP, Lin, J, Weiss, A. Signal transduction by the TCR for antigen. Curr Opin Immunol 2000; 12:242. Copyright &copy; 2000 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34083=[""].join("\n");
var outline_f33_18_34083=null;
var title_f33_18_34084="Waardenburg syndrome";
var content_f33_18_34084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Waardenburg syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A white forelock, broad nasal root and dystopia canthorum in the father, and heterochromatic irides in the son affected by Waardenburg syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nayak CS, Isaacson G. Worldwide distribution of Waardenburg syndrome. Ann Otol Rhinol Laryngol 2003; 112:817. Copyright &copy; 2003 Annals Publishing Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34084=[""].join("\n");
var outline_f33_18_34084=null;
var title_f33_18_34085="Palonosetron: Drug information";
var content_f33_18_34085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Palonosetron: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/57/36755?source=see_link\">",
"    see \"Palonosetron: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26916?source=see_link\">",
"    see \"Palonosetron: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14877561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aloxi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Selective 5-HT",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chemotherapy-associated nausea and vomiting:",
"     </b>",
"     I.V.: 0.25 mg 30 minutes prior to the start of chemotherapy administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Breakthrough:",
"     </i>",
"     Palonosetron has not been shown to be effective in terminating nausea or vomiting once it occurs and should not be used for this purpose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PONV:",
"     </b>",
"     I.V.: 0.075 mg immediately prior to anesthesia induction",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F205845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F205846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F205847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aloxi&reg;: 0.05 mg/mL (5 mL) [contains edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F205826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flush I.V. line with NS prior to and following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chemotherapy-associated nausea and vomiting: Infuse over 30 seconds, 30 minutes prior to the start of chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PONV: Infuse over 10 seconds immediately prior to anesthesia induction",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3137181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, and D",
"     <sub>",
"      5",
"     </sub>",
"     LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Ampicillin/sulbactam, atropine, carboplatin, cefazolin, cefotetan, cisatracurium, cisplatin, cyclophosphamide, dacarbazine, docetaxel, doxorubicin, epirubicin, famotidine, fentanyl, fluorouracil, gemcitabine, gentamicin, glycopyrrolate, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, ifosfamide, irinotecan, lidocaine, lorazepam, mannitol, meperidine, metoclopramide, metronidazole, midazolam, morphine, neostigmine, oxaliplatin, paclitaxel, potassium chloride, promethazine, propofol, rocuronium, succinylcholine, sufentanil, topotecan, vancomycin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fosaprepitant, methylprednisolone sodium succinate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe:",
"     </b>",
"     Compatible: Dexamethasone sodium phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of chemotherapy-associated nausea and vomiting; indicated for prevention of acute (highly-emetogenic therapy) as well as acute and delayed (moderately-emetogenic therapy) nausea and vomiting; prevention of postoperative nausea and vomiting (PONV)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aloxi&reg; may be confused with Eloxatin&reg;, oxaliplatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Palonosetron may be confused with dolasetron, granisetron, ondansetron",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events may vary according to indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: QT prolongation (chemotherapy-associated &lt;1%; PONV 1% to 5%), bradycardia (chemotherapy-associated 1%; PONV 4%), hypotension (&le;1%), sinus bradycardia (&le;1%), tachycardia (nonsustained) (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (chemotherapy-associated 5% to 9%; PONV 3%), anxiety (1%), dizziness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (2% to 5%), diarrhea (&le;1%), flatulence (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (&le;1%; transient), AST increased (&le;1%; transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain,  allergic dermatitis, amblyopia, anemia, anorexia, appetite decreased, arrhythmia, arthralgia, bilirubin increased (transient), chills, dyspepsia, edema (generalized), electrolyte fluctuations, epistaxis, erythema, euphoric mood, extrasystoles, eye irritation, fatigue, fever, flu-like syndrome, glycosuria, hiccups, hot flash, hyperglycemia, hypersensitivity (rare), hypersomnia, hypertension, hypokalemia, hypoventilation, injection site reactions (burning/discomfort/induration/pain; rare), insomnia, intestinal hypomotility, laryngospasm, metabolic acidosis, motion sickness, myocardial ischemia, pain in extremities, paresthesia, platelets decreased, rash, salivation increased, seizure, sinus arrhythmia, sinus tachycardia, somnolence, supraventricular extrasystoles, tinnitus, T-wave amplitude decreased, vein discoloration, vein distention, ventricular extrasystoles, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to palonosetron or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity has been observed rarely with I.V. palonosetron. Use with caution in patients allergic to other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists; cross-reactivity has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ECG effects: Some selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists have been associated with dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QT",
"     <sub>",
"      c",
"     </sub>",
"     , JT), usually occurring 1-2 hours after I.V. administration. In general, these changes are not clinically relevant, however, when these agents are used in conjunction with other agents that prolong these intervals, arrhythmia may occur. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics), clinically relevant QT interval prolongation could result in torsade de pointes. A number of trials have shown that 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists produce QT interval prolongation to variable degrees. Use with caution in patients at risk of QT prolongation and/or ventricular arrhythmia. Reduction in heart rate may also occur with the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long QT syndrome: Use with caution in patients with congenital long QT syndrome or other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], and cumulative high-dose anthracycline therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemotherapy-associated emesis:",
"     <b>",
"      For chemotherapy, should be used on a scheduled basis, not on an \"as needed\" (PRN) basis,",
"     </b>",
"     since data support the use of this drug only in the prevention of nausea and vomiting (due to antineoplastic therapy) and not in the rescue of nausea and vomiting. Not intended for treatment of nausea and vomiting or for chronic continuous therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PONV: Use is not recommended if there is little expectation of PONV; may use for low expectation of PONV if it is essential to avoid nausea and vomiting in the postoperative period.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F205854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F205832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The extent to which palonosetron is excreted in breast milk, if at all, is unknown. Due to the potential for adverse effects in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5062442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aloxi Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/5 mL (5 mL): $454.80",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aloxi (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TH, TR, TW);",
"     </li>",
"     <li>",
"      Lowvo (CL);",
"     </li>",
"     <li>",
"      Onicit (AR, BR, CN, CO, DO, GT, HN, MX, NI, PE, SV, VE);",
"     </li>",
"     <li>",
"      Paloxi (ID, IL, KP);",
"     </li>",
"     <li>",
"      Palzen (IN);",
"     </li>",
"     <li>",
"      Zhirvo (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonist, blocking serotonin, both on vagal nerve terminals in the periphery and centrally in the chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8.3 &plusmn; 2.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~62%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: ~50% metabolized via CYP enzymes (and likely other pathways) to relatively inactive metabolites (N-oxide-palonosetron and 6-S-hydroxy-palonosetron); CYP1A2, 2D6, and 3A4 contribute to its metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: Terminal: ~40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% to 93%, 40% as unchanged drug); feces (5% to 8%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aapro MS, Grunberg SM, Manikhas GM, et al, &ldquo;A Phase III, Double-Blind, Randomized Trial of Palonosetron Compared With Ondansetron in Preventing Chemotherapy-Induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2006, 17(9):1441-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/16766588/pubmed\" id=\"16766588\" target=\"_blank\">",
"        16766588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boccia RV, Gonzalez EF, Pluzanska AG, et al, &ldquo;Palonosetron (PALO), Administered Orally or Intravenously (IV), Plus Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15 Supp):20608 [abstract 20608 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisenberg P, Figueroa-Vadillo J, Zamora R, et al, &ldquo;Improved Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting With Palonosetron, a Pharmacologically Novel 5-HT3 Receptor Antagonist: Results of a Phase III, Single-Dose Trial Versus Dolasetron,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 98(11):2473-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/14635083/pubmed\" id=\"14635083\" target=\"_blank\">",
"        14635083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisenberg P, MacKintosh FR, Ritch P, et al, &ldquo;Efficacy, Safety and Pharmacokinetics of Palonosetron in Patients Receiving Highly Emetogenic Cisplatin-Based Chemotherapy: A Dose-Ranging Clinical Study,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(2):330-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/14760130/pubmed\" id=\"14760130\" target=\"_blank\">",
"        14760130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gralla R, Lichinister M, Van Der Vegt S, et al, &ldquo;Palonosetron Improves Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy: Results of a Double-Blind Randomized Phase III Trial Comparing Single Doses of Palonosetron With Ondansetron,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2003, 14(10):1570-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/14504060/pubmed\" id=\"14504060\" target=\"_blank\">",
"        14504060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kris MG, Hesketh PJ, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2932-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kupiec TC, Trusley C, Ben M, et al, &ldquo;Physical and Chemical Stability of Palonosetron Hydrochloride With Five Common Parenteral Drugs During Simulated Y-Site Administration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2008, 65(18):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/18769000/pubmed\" id=\"18769000\" target=\"_blank\">",
"        18769000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Multinational Association of Supportive Care in Cancer (MASCC), &ldquo;Antiemetic Guidelines,&rdquo; Updated April 2010. Available at file://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2010.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tang J, D'Angelo R, White PF, et al, &ldquo;The Efficacy of RS-25259, A Long-Acting Selective 5-HT",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1998, 87(2):462-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/9706951/pubmed\" id=\"9706951\" target=\"_blank\">",
"        9706951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Trusley C, Ben M, et al, &ldquo;Physical and Chemical Stability of Palonosetron Hydrochloride With Five Opiate Agonists During Simulated Y-Site Administration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64 (11):1209-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/17519464/pubmed\" id=\"17519464\" target=\"_blank\">",
"        17519464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA and Xu QA, &ldquo;Physical and Chemical Stability of Palonosetron HCl in 4 Infusion Solutions,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38(10):1608-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/15328393/pubmed\" id=\"15328393\" target=\"_blank\">",
"        15328393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA and Zhang Y. &ldquo;Compatibility and Stability of Aloxi (Palonosetron Hydrochloride) Admixed With Dexamethasone Sodium Phosphate,&rdquo;",
"      <i>",
"       Intl J Pharm Compounding",
"      </i>",
"      , 2004, 8(5):398-403.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA and Zhang Y, &ldquo;Palonosetron HCl Compatibility and Stability with Doxorubicin HCl and Epirubicin HCl During Simulated Y-Site Administration,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(2):280-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/15613463/pubmed\" id=\"15613463\" target=\"_blank\">",
"        15613463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Xu QA, and Trissel LA, &ldquo;Compatibility of Palonosetron With Cyclophosphamide and With Ifosfamide During Simulated Y-site Administration,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2005, 62(19):1998-2000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/16174835/pubmed\" id=\"16174835\" target=\"_blank\">",
"        16174835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zambelli A, Sagrada P, and Pavesi L, &ldquo;Seizure Associated With Palonosetron,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2009, 17(3):217.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/18/34085/abstract-text/19139929/pubmed\" id=\"19139929\" target=\"_blank\">",
"        19139929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9944 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34085=[""].join("\n");
var outline_f33_18_34085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14877561\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205861\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205844\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205845\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205846\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205847\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205824\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205812\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205826\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3137181\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205825\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205868\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205859\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205829\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205815\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205854\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205819\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205821\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205831\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205850\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205832\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5062442\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539911\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205814\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205828\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9944\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9944|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/57/36755?source=related_link\">",
"      Palonosetron: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26916?source=related_link\">",
"      Palonosetron: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_18_34086="Atrial flutter CS massage";
var content_f33_18_34086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1115px;\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Atrial flutter at a rate of 250 beats/min with 2:1 AV conduction in the presence of left bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 117px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although every other flutter wave can be seen at the end of the T wave in the first part of the tracing (arrows), a sinus mechanism cannot be excluded. The flutter waves become clearly apparent after carotid sinus massage is applied to slow conduction through the AV node, thereby increasing the degree of AV block.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34086=[""].join("\n");
var outline_f33_18_34086=null;
var title_f33_18_34087="Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)";
var content_f33_18_34087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34087/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34087/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34087/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34087/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/18/34087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is a complex syndrome of varying intensity, clinical presentation, and natural history rather than a single, uniform disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It represents an immunologic reaction to an inhaled agent, particularly an organic antigen, occurring within the pulmonary parenchyma. Numerous inciting agents have been described, including, but not limited to, agricultural dusts, bioaerosols, and certain reactive chemical species.",
"   </p>",
"   <p>",
"    The epidemiology and etiologic agents of HP will be reviewed here. The major classes are discussed in the text, while the individual causes are listed in the tables. The clinical features, diagnosis, and management of HP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/49/19222?source=see_link\">",
"     \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7719?source=see_link\">",
"     \"Treatment and prognosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of HP remains largely unknown. The prevalence and incidence are thought to be low, but few population-based studies have been conducted to address this question. Much of the epidemiologic information regarding HP has been derived from studies of farmers and bird fanciers.",
"   </p>",
"   <p>",
"    Based upon these studies, the prevalence and incidence of HP appear to vary considerably depending upon case definitions, intensity of exposure to inciting antigens, season, geographical conditions, local practices and customs, proximity to certain industries, and host risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Many persons with mild or subclinical HP escape detection or are misdiagnosed as suffering from viral illnesses or asthma, either of which may have nonspecific clinical findings which mimic HP.",
"   </p>",
"   <p>",
"    Only a small proportion of exposed individuals develop clinically significant HP, and genetic factors have been postulated to play a major role in determining an individual's risk of disease. As an example, one study of 44 patients with HP related to pigeon exposure, 50 exposed but asymptomatic individuals, and 99 healthy, unexposed controls found significant associations between HP and the presence of a number of specific MHC class II alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/5\">",
"     5",
"    </a>",
"    ]. It is likely that the immunologic abnormalities which underlie HP reflect the interplay of multiple genes involved in the immune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Farmer's lung is one of the most common forms of HP, affecting 0.4 to 7 percent of the farming population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Prevalence (the number of cases in the population at risk at a given time) varies by region, climate, and farming practices from approximately 9 percent of farmers at risk in humid zones to 2 percent in drier zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This variation is illustrated by the differences in the prevalence (per 100,000) of farmer's lung in several countries:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      United States &ndash; 420 to 3000 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      United Kingdom &ndash; 12 to 2300 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      France &ndash; 4370 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Finland &ndash; 1400 to 1700 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reported prevalence of HP among bird fanciers is even more variable; estimates range from 20 to 20,000 affected individuals per 100,000 persons at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The prevalence of HP is likely to be higher among bird fanciers than among farmers because contact with the inciting avian antigens is less limited by season or geographic location. The species of birds raised and the handling practices employed may affect prevalence, but data regarding such variables are sparse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HP (number of new cases in the population at risk in a given year) varies considerably and is influenced by similar factors. In Finland, for example, significant variation in incidence according to season has been noted: most cases of farmer's lung occur in April near the end of the indoor feeding season for cattle, while the incidence is lowest in October, when outdoor feeding is the norm. The incidence of farmer's lung also correlates positively with the average daily rainfall during the preceding haymaking period.",
"   </p>",
"   <p>",
"    Despite some variation among study populations, the incidence rate of HP among pigeon breeders clearly is higher than that among farmers. Whereas the incidence rate of HP among farmers is between 8 and 540 per 100,000 per year, pigeon breeders have had rates of 6000 to 21,000 per 100,000 per year (ie, 6 to 21 percent per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/7,15,16,19,20\">",
"     7,15,16,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High attack rates have also been documented during sporadic outbreaks of HP among other populations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      52 percent of exposed office workers with humidifier lung [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      37 percent of lifeguards exposed to a public swimming pool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      27 percent of workers at an injection molding plant manufacturing polyurethane foam parts for automobiles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      15 percent of office workers exposed to a contaminated forced air system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is associated with a",
"    <strong>",
"     decreased",
"    </strong>",
"    risk of HP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. As examples, smoking appears to diminish the risk of developing farmer's lung, pigeon breeder's disease, HP associated with contaminated air conditioners, and Japanese summer-type HP caused by Trichosporon cutaneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Once the disease is established, however, smoking does not appear to attenuate its severity, and may predispose to a more chronic and severe course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations may reflect diminished antibody responses to inhaled antigens among smokers despite similar degrees of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/28,30,31\">",
"     28,30,31",
"    </a>",
"    ]. In a survey of 102 pigeon breeders, for example, an IgG antibody response to inhaled pigeon antigens was much less common among smokers (4 versus 55 percent in nonsmokers). This effect of smoking appeared to be reversible, since former smokers had a response similar to that of nonsmokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of occupations and avocations that result in contact with airborne organic antigens increase the risk of developing HP. Over 300 etiologies of HP have been reported. Some of these entities are derived from reports of a single or small number of cases and require further study. The following tables list reported etiologies of HP by occupation and describe the major causative antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/3,7,32-53\">",
"     3,7,32-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Farming, vegetable, or dairy cattle workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Farmer's lung is, as noted above, one of the most common forms of HP. There are several types of exposure and many different antigens that must be considered in farmers and cattle workers (",
"    <a class=\"graphic graphic_table graphicRef69245 \" href=\"mobipreview.htm?10/47/11004\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HP in farmers must be distinguished from febrile, toxic reactions to inhaled mold dusts (organic dust toxic syndrome [ODTS]). ODTS is a nonimmunologic reaction that occurs",
"    <strong>",
"     30 to 50",
"    </strong>",
"    times more commonly than HP in farmers. HP is associated with high exposure on most days for prolonged periods, while ODTS is associated with intense exposure occurring on a single day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ventilation and water-related contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;HP occurs when there is exposure to antigens of microorganisms which colonize forced air systems, heated water reservoirs, portable ultrasonic humidifiers, cool-mist vaporizers, wooden water buckets, swimming pools, whirlpools, hot tubs, spas, water flume slides, water-damaged carpeting, or shower curtains (",
"    <a class=\"graphic graphic_table graphicRef53834 \" href=\"mobipreview.htm?31/62/32747\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/22,38-40\">",
"     22,38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mycobacterium avium complex (MAC) is a pathogenic organism in patients with underlying lung disease or compromised immunity; in addition, MAC may cause HP in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. Affected individuals often have a history of hot tub exposure, and the resulting HP has been referred to as \"hot tub lung\". This condition results in granulomatous inflammation, and avoidance of ongoing exposure is the cornerstone of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/54,59\">",
"     54,59",
"    </a>",
"    ]. In contrast, true MAC infection may require long-term antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bird and poultry handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;HP can be induced by exposure to excreta and proteinaceous material on dried, finely dispersed dust from pigeons and other birds and fowl (",
"    <a class=\"graphic graphic_table graphicRef72774 \" href=\"mobipreview.htm?7/56/8075\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Among the mechanisms by which this can occur are aerosol spread of droppings by the vent of a clothes dryer, contamination of heating vents from a garage where the birds were housed, and exposure to feather pillows, wreaths, and down comforters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/60,62\">",
"     60,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Veterinary work and animal handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;These occupations involve significant contact with animals and associated organic antigens. A variety of HP syndromes have resulted (",
"    <a class=\"graphic graphic_table graphicRef60922 \" href=\"mobipreview.htm?21/13/21723\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Grain and flour processing and loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the course of processing, grain may become colonized with a variety of microorganisms and insect pathogens, such as Sporobolomyces, Aspergillus fumigatus, Aspergillus clavatus, and Sitophilus granarius (weevil). The grain is easily aerosolized, and significant exposure to inhaled organic antigens may ensue and lead to HP (",
"    <a class=\"graphic graphic_table graphicRef52325 \" href=\"mobipreview.htm?4/39/4731\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/41,63\">",
"     41,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lumber milling, construction, wood stripping, paper and wallboard manufacture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trees, plants, and their products can become colonized with mold. Occupations that place an individual in contact with colonized plant products may lead to several varieties of HP (",
"    <a class=\"graphic graphic_table graphicRef69067 \" href=\"mobipreview.htm?10/62/11244\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Plastic manufacture, painting, electronics industry, other chemicals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some inciting agents capable of causing HP may be synthetic in origin. Occupational exposure to aerosolized or gas phase organic chemicals may result in HP (",
"    <a class=\"graphic graphic_table graphicRef68812 \" href=\"mobipreview.htm?28/60/29643\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/45-51\">",
"     45-51",
"    </a>",
"    ]. These workers are also at increased risk for the development of occupational asthma or rhinitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Textile workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary manifestations in the following exposures are probably not true forms of HP, but they are included for completeness (",
"    <a class=\"graphic graphic_table graphicRef51108 \" href=\"mobipreview.htm?6/53/7003\">",
"     table 8",
"    </a>",
"    ). These exposures lead to lung injury characterized pathologically by diffuse alveolar damage, desquamative interstitial pneumonitis, or other forms of pulmonary pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34087/abstract/53\">",
"     53",
"    </a>",
"    ]. A specific form of textile-related lung disease has been identified in workers exposed to rotary-cut nylon flock, and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28629?source=see_link\">",
"     \"Nylon flock worker's lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169827\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, represents an immunologic reaction to an inhaled agent, particularly an organic antigen, occurring within the pulmonary parenchyma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence and incidence of HP appear to vary considerably depending upon case definitions, intensity of exposure to inciting antigens, season, geographical conditions, local practices and customs, proximity to certain industries, and host risk factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide range of occupations and avocations that result in contact with airborne organic antigens increase the risk of developing HP; over 300 etiologies of HP have been reported. Occupations and activities associated with HP and their associated antigens are listed in the tables:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Farming, vegetable and dairy cattle workers (",
"      <a class=\"graphic graphic_table graphicRef69245 \" href=\"mobipreview.htm?10/47/11004\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Farming, vegetable, or dairy cattle workers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to ventilation systems and water reservoirs (",
"      <a class=\"graphic graphic_table graphicRef53834 \" href=\"mobipreview.htm?31/62/32747\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ventilation and water-related contamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bird and poultry handlers (",
"      <a class=\"graphic graphic_table graphicRef72774 \" href=\"mobipreview.htm?7/56/8075\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bird and poultry handling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Animal handlers (",
"      <a class=\"graphic graphic_table graphicRef60922 \" href=\"mobipreview.htm?21/13/21723\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Veterinary work and animal handling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Grain and flour processing (",
"      <a class=\"graphic graphic_table graphicRef52325 \" href=\"mobipreview.htm?4/39/4731\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Grain and flour processing and loading'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumber milling, construction, bark stripping (",
"      <a class=\"graphic graphic_table graphicRef69067 \" href=\"mobipreview.htm?10/62/11244\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Lumber milling, construction, wood stripping, paper and wallboard manufacture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plastics,",
"      <span class=\"nowrap\">",
"       paint/epoxy,",
"      </span>",
"      electronics industries (",
"      <a class=\"graphic graphic_table graphicRef68812 \" href=\"mobipreview.htm?28/60/29643\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Plastic manufacture, painting, electronics industry, other chemicals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Textile workers (",
"      <a class=\"graphic graphic_table graphicRef51108 \" href=\"mobipreview.htm?6/53/7003\">",
"       table 8",
"      </a>",
"      ). The pulmonary manifestations of textile exposures such as byssinosis and &ldquo;flock workers&rsquo; lung are probably not true forms of HP, (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Textile workers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28629?source=see_link\">",
"       \"Nylon flock worker's lung\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation, diagnosis, and treatment of hypersensitivity pneumonitis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/49/19222?source=see_link\">",
"       \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1225?source=see_link\">",
"       \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7719?source=see_link\">",
"       \"Treatment and prognosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/1\">",
"      Cormier, Y, Lacasse, Y. Keys to the diagnosis of hypersensitivity pneumonitis: The role of serum precipitins, lung biopsy, and high-resolution computed tomography. Clin Pulm Med 1996; 3:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/2\">",
"      Rose C, King TE Jr. Controversies in hypersensitivity pneumonitis. Am Rev Respir Dis 1992; 145:1.",
"     </a>",
"    </li>",
"    <li>",
"     Selman M. Hypersensitivity pneumonitis. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), BC Decker, Hamilton, ON, Canada 2003. p.452.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/4\">",
"      Lopez M, Salvaggio JE. Epidemiology of hypersensitivity pneumonitis/allergic alveolitis. Monogr Allergy 1987; 21:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/5\">",
"      Camarena A, Ju&aacute;rez A, Mej&iacute;a M, et al. Major histocompatibility complex and tumor necrosis factor-alpha polymorphisms in pigeon breeder's disease. Am J Respir Crit Care Med 2001; 163:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/6\">",
"      Lalancette M, Carrier G, Laviolette M, et al. Farmer's lung. Long-term outcome and lack of predictive value of bronchoalveolar lavage fibrosing factors. Am Rev Respir Dis 1993; 148:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/7\">",
"      Salvaggio JE. The identification of hypersensitivity pneumonitis. Hosp Pract (Minneap) 1995; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/8\">",
"      Dalphin JC, Debieuvre D, Pernet D, et al. Prevalence and risk factors for chronic bronchitis and farmer's lung in French dairy farmers. Br J Ind Med 1993; 50:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/9\">",
"      Grant IW, Blyth W, Wardrop VE, et al. Prevalence of farmer's lung in Scotland: a pilot survey. Br Med J 1972; 1:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/10\">",
"      Gruchow HW, Hoffmann RG, Marx JJ Jr, et al. Precipitating antibodies to farmer's lung antigens in a Wisconsin farming population. Am Rev Respir Dis 1981; 124:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/11\">",
"      Madsen D, Klock LE, Wenzel FJ, et al. The prevalence of farmer's lung in an agricultural population. Am Rev Respir Dis 1976; 113:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/12\">",
"      Staines FH, Forman JA. A Survey of \" Farmer's Lung \". J Coll Gen Pract 1961; 4:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/13\">",
"      Pether JV, Greatorex FB. Farmer's lung disease in Somerset. Br J Ind Med 1976; 33:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/14\">",
"      Depierre A, Dalphin JC, Pernet D, et al. Epidemiological study of farmer's lung in five districts of the French Doubs province. Thorax 1988; 43:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/15\">",
"      Terho EO, Husman K, Vohlonen I. Prevalence and incidence of chronic bronchitis and farmer's lung with respect to age, sex, atopy, and smoking. Eur J Respir Dis Suppl 1987; 152:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/16\">",
"      Terho EO. Work-related respiratory disorders among Finnish farmers. Am J Ind Med 1990; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/17\">",
"      Christensen LT, Schmidt CD, Robbins L. Pigeon breeders' disease--a prevalence study and review. Clin Allergy 1975; 5:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/18\">",
"      Hendrick DJ, Faux JA, Marshall R. Budgerigar-fancier's lung: the commonest variety of allergic alveolitis in Britain. Br Med J 1978; 2:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/19\">",
"      Terho EO, Heinonen OP, Lammi S, Laukkanen V. Incidence of clinically confirmed farmer's lung in Finland and its relation to meteorological factors. Eur J Respir Dis Suppl 1987; 152:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/20\">",
"      Malmberg P, Rask-Andersen A, H&ouml;glund S, et al. Incidence of organic dust toxic syndrome and allergic alveolitis in Swedish farmers. Int Arch Allergy Appl Immunol 1988; 87:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/21\">",
"      Ganier M, Lieberman P, Fink J, Lockwood DG. Humidifier lung. An outbreak in office workers. Chest 1980; 77:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/22\">",
"      Rose CS, Martyny JW, Newman LS, et al. \"Lifeguard lung\": endemic granulomatous pneumonitis in an indoor swimming pool. Am J Public Health 1998; 88:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/23\">",
"      Simpson C, Garabrant D, Torrey S, et al. Hypersensitivity pneumonitis-like reaction and occupational asthma associated with 1,3-bis(isocyanatomethyl) cyclohexane pre-polymer. Am J Ind Med 1996; 30:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/24\">",
"      Banaszak EF, Thiede WH, Fink JN. Hypersensitivity pneumonitis due to contamination of an air conditioner. N Engl J Med 1970; 283:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/25\">",
"      Murin S, Bilello KS, Matthay R. Other smoking-affected pulmonary diseases. Clin Chest Med 2000; 21:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/26\">",
"      Solaymani-Dodaran M, West J, Smith C, Hubbard R. Extrinsic allergic alveolitis: incidence and mortality in the general population. QJM 2007; 100:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/27\">",
"      Arima K, Ando M, Ito K, et al. Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum. Arch Environ Health 1992; 47:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/28\">",
"      McSharry C, Banham SW, Boyd G. Effect of cigarette smoking on the antibody response to inhaled antigens and the prevalence of extrinsic allergic alveolitis among pigeon breeders. Clin Allergy 1985; 15:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/29\">",
"      Ohtsuka Y, Munakata M, Tanimura K, et al. Smoking promotes insidious and chronic farmer's lung disease, and deteriorates the clinical outcome. Intern Med 1995; 34:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/30\">",
"      Kusaka H, Homma Y, Ogasawara H, et al. Five-year follow-up of Micropolyspora faeni antibody in smoking and nonsmoking farmers. Am Rev Respir Dis 1989; 140:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/31\">",
"      Dangman KH, Storey E, Schenck P, Hodgson MJ. Effects of cigarette smoking on diagnostic tests for work-related hypersensitivity pneumonitis: data from an outbreak of lung disease in metalworkers. Am J Ind Med 2004; 45:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/32\">",
"      Reynolds HY. Hypersensitivity pneumonitis. Clin Chest Med 1982; 3:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/33\">",
"      Reed CE. Hypersensitivity pneumonitis. Postgrad Med 1972; 51:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/34\">",
"      Kaltreider HB. Hypersensitivity pneumonitis. West J Med 1993; 159:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/35\">",
"      Gurney JW. Hypersensitivity pneumonitis. Radiol Clin North Am 1992; 30:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/36\">",
"      Malmberg P, Rask-Andersen A, Rosenhall L. Exposure to microorganisms associated with allergic alveolitis and febrile reactions to mold dust in farmers. Chest 1993; 103:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/37\">",
"      Lander F, Jepsen JR, Gravesen S. Allergic alveolitis and late asthmatic reaction due to molds in the tobacco industry. Allergy 1988; 43:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/38\">",
"      Rose CS. Water-related lung diseases. Occup Med 1992; 7:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/39\">",
"      Kane GC, Marx JJ, Prince DS. Hypersensitivity pneumonitis secondary to Klebsiella oxytoca. A new cause of humidifier lung. Chest 1993; 104:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/40\">",
"      Jacobs RL, Thorner RE, Holcomb JR, et al. Hypersensitivity pneumonitis caused by Cladosporium in an enclosed hot-tub area. Ann Intern Med 1986; 105:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/41\">",
"      Mitsuhashi M, Tamura H, Morikawa A, Kuroume T. A unique substance from the granary weevil: nonspecific immunoglobulin binding substance. Int Arch Allergy Appl Immunol 1983; 72:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/42\">",
"      Alegre J, Morell F, Cobo E. Respiratory symptoms and pulmonary function of workers exposed to cork dust, toluene diisocyanate and conidia. Scand J Work Environ Health 1990; 16:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/43\">",
"      Gamboa PM, de las Marinas MD, Ant&eacute;para I, et al. Extrinsic allergic alveolitis caused by esparto (Stipa tenacissima). Allergol Immunopathol (Madr) 1990; 18:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/44\">",
"      Zamarr&oacute;n C, del Campo F, Paredes C. Extrinsic allergic alveolitis due to exposure to esparto dust. J Intern Med 1992; 232:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/45\">",
"      Zeiss CR, Kanellakes TM, Bellone JD, et al. Immunoglobulin E-mediated asthma and hypersensitivity pneumonitis with precipitating anti-hapten antibodies due to diphenylmethane diisocyanate (MDI) exposure. J Allergy Clin Immunol 1980; 65:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/46\">",
"      Mapp CE, Dal Vecchio L, Boschetto P, Fabbri LM. Combined asthma and alveolitis due to diphenylmethane diisocyanate (MDI) with demonstration of no crossed respiratory reactivity to toluene diisocyanate (TDI). Ann Allergy 1985; 54:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/47\">",
"      Vandenplas O, Malo JL, Dugas M, et al. Hypersensitivity pneumonitis-like reaction among workers exposed to diphenylmethane [correction to piphenylmethane] diisocyanate (MDI). Am Rev Respir Dis 1993; 147:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/48\">",
"      Yoshizawa Y, Ohtsuka M, Noguchi K, et al. Hypersensitivity pneumonitis induced by toluene diisocyanate: sequelae of continuous exposure. Ann Intern Med 1989; 110:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/49\">",
"      Bernstein DI, Lummus ZL, Santilli G, et al. Machine operator's lung. A hypersensitivity pneumonitis disorder associated with exposure to metalworking fluid aerosols. Chest 1995; 108:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Biopsy-confirmed hypersensitivity pneumonitis in automobile production workers exposed to metalworking fluids--Michigan, 1994-1995. MMWR Morb Mortal Wkly Rep 1996; 45:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/51\">",
"      Robertson W, Robertson AS, Burge CB, et al. Clinical investigation of an outbreak of alveolitis and asthma in a car engine manufacturing plant. Thorax 2007; 62:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/52\">",
"      Kern, DG, Durand, KTH, Crausman, RS, et al. Nonspecific interstitial pneumonia in the synthetic textile industry. Am J Respir Crit Care Med 1997; 155:A810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/53\">",
"      Lougheed MD, Roos JO, Waddell WR, Munt PW. Desquamative interstitial pneumonitis and diffuse alveolar damage in textile workers. Potential role of mycotoxins. Chest 1995; 108:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/54\">",
"      Cappelluti E, Fraire AE, Schaefer OP. A case of \"hot tub lung\" due to Mycobacterium avium complex in an immunocompetent host. Arch Intern Med 2003; 163:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/55\">",
"      Khoor A, Leslie KO, Tazelaar HD, et al. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol 2001; 115:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/56\">",
"      Kahana LM, Kay JM, Yakrus MA, Waserman S. Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure. Chest 1997; 111:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/57\">",
"      Embil J, Warren P, Yakrus M, et al. Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection? Chest 1997; 111:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/58\">",
"      Myers JL, Tazelaar HD. Challenges in pulmonary fibrosis: 6--Problematic granulomatous lung disease. Thorax 2008; 63:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/59\">",
"      Hanak V, Golbin JM, Ryu JH. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. Mayo Clin Proc 2007; 82:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/60\">",
"      Morell F, Roger A, Reyes L, et al. Bird fancier's lung: a series of 86 patients. Medicine (Baltimore) 2008; 87:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/61\">",
"      Chan AL, Juarez MM, Leslie KO, et al. Bird Fancier's Lung: A State-of-the-Art Review. Clin Rev Allergy Immunol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/62\">",
"      Inase N, Ohtani Y, Sumi Y, et al. A clinical study of hypersensitivity pneumonitis presumably caused by feather duvets. Ann Allergy Asthma Immunol 2006; 96:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34087/abstract/63\">",
"      Cockcroft DW, Berscheid BA, Ramshaw IA, Dolovich J. Sporobolomyces: a possible cause of extrinsic allergic alveolitis. J Allergy Clin Immunol 1983; 72:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4309 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34087=[""].join("\n");
var outline_f33_18_34087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1169827\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Farming, vegetable, or dairy cattle workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ventilation and water-related contamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bird and poultry handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Veterinary work and animal handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Grain and flour processing and loading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lumber milling, construction, wood stripping, paper and wallboard manufacture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Plastic manufacture, painting, electronics industry, other chemicals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Textile workers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169827\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4309|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/47/11004\" title=\"table 1\">",
"      Farmers lung antigens in HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/62/32747\" title=\"table 2\">",
"      Water related antigens in HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/56/8075\" title=\"table 3\">",
"      Poultry related antigens in HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/13/21723\" title=\"table 4\">",
"      Animal handling antigens in HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/39/4731\" title=\"table 5\">",
"      Grain processing antigens in HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/62/11244\" title=\"table 6\">",
"      Lumber mill antigens in HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/60/29643\" title=\"table 7\">",
"      Chemical exposure antigen in HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/53/7003\" title=\"table 8\">",
"      Textile workers antigens in HP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/49/19222?source=related_link\">",
"      Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28629?source=related_link\">",
"      Nylon flock worker's lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7719?source=related_link\">",
"      Treatment and prognosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_18_34088="Membranous nephropathy and renal transplantation";
var content_f33_18_34088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Membranous nephropathy and renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34088/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34088/contributors\">",
"     Jean Francis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34088/contributors\">",
"     Laurence H Beck, Jr, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34088/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34088/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/18/34088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26073572\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy (MN) may occur in the transplanted kidney, either as recurrent disease in patients who had MN as the cause of end stage renal disease in the native kidney or de novo in patients who had another cause of end stage renal disease initially. This topic reviews both recurrent and de novo MN in the transplanted kidney.",
"   </p>",
"   <p>",
"    The causes, diagnosis and treatment of MN in the native kidney are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recurrence of other glomerular diseases in the transplanted kidney is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32614?source=see_link\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39367?source=see_link\">",
"     \"IgA nephropathy: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150862\">",
"    <span class=\"h1\">",
"     RECURRENT MEMBRANOUS NEPHROPATHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151105\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of recurrent MN ranges between 10 and 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. The reason for the wide variability is that the diagnosis is made only by biopsy and the indications for biopsy vary between transplant centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/11\">",
"     11",
"    </a>",
"    ]. Centers that perform protocol biopsies in the absence of symptoms generally report a higher incidence. The best data are from one study of 19 patients with MN who underwent surveillance biopsies after transplantation of which recurrent MN was detected in 8 (42 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial reports suggested that patients with living-related transplants are at higher risk for recurrence than those who receive deceased-donor grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. However, this has not been confirmed by larger studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In one study of 35 patients with MN who received a kidney allograft between 1975 and 2008, 12 patients (34 percent) developed recurrent MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/10\">",
"     10",
"    </a>",
"    ]. Although the rate of recurrence was modestly higher among patients who had a living related transplant compared to those who received a deceased donor allograft (4 of 8, or 50 percent versus 8 of 27 or 30 percent, respectively), the difference was not significant. Two other series that included a total of 53 patients were also unable to confirm a higher risk associated with living-related transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No other risk factors for recurrence have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150994\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of idiopathic MN is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The occasionally rapid recurrence of MN following transplantation suggests the presence of a circulating factor that may be present at the time of transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9\">",
"     9",
"    </a>",
"    ]. This factor could be an autoantibody to the M-type phospholipase A2 receptor (PLA2R), which has been implicated in MN pathogenesis. Autoantibodies against PLA2R have been reported in patients with recurrent MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In one such patient who developed recurrent disease 13 days after transplantation, PLA2R and monotypic IgG3 were co-localized in glomerular deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/16\">",
"     16",
"    </a>",
"    ]. This patient was also shown to have circulating anti-PLA2R antibodies of the same IgG3 kappa subclass that was present in glomerular deposits of both the native kidney and the allograft, strongly suggesting that this antibody caused the glomerular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of one such patient with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was associated with a reduction in the level of anti-PLA2R and a decrease in proteinuria, suggesting a link between the autoantibody level and disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Phospholipase A2 receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other autoantibodies have been identified in patients with primary MN but not recurrent MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152029\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of recurrent MN are typically observed 13 to 15 months after transplantation although they may be observed much earlier (within weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ]. The most common clinical manifestation is proteinuria, the degree of which may vary on presentation. In one study of fifteen patients with recurrent MN, twelve (80 percent) had protein excretion greater than 150",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    h (or a protein to creatinine ratio greater than 200",
"    <span class=\"nowrap\">",
"     mg/g),",
"    </span>",
"    with eight having nephrotic range proteinuria (ie, greater than 3.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protein excretion may be lower among those with recurrent MN detected by protocol biopsy and without overt signs or symptoms of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one study of 8 patients with recurrent MN diagnosed by surveillance biopsies, three had normal protein excretion and five had protein excretion greater than 150",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    but less than 3",
"    <span class=\"nowrap\">",
"     g/d",
"    </span>",
"    at the time of biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progression of proteinuria is common even among patients with mild or no proteinuria on presentation. As an example, in the study cited above, of seven patients who did not receive additional immunosuppression for recurrent MN, 5 had significant increases in protein excretion and three developed nephrotic range proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8\">",
"     8",
"    </a>",
"    ]. In another study, among 29 patients, the median proteinuria increased from 331",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at diagnosis to 1409",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    during a mean of 19 months of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glomerular filtration is often normal or only mildly decreased on initial presentation. In the study cited above of 15 patients with recurrent MN, there was no significant difference in serum creatinine at the time of diagnosis compared to patients who did not have recurrent MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the GFR often falls with progression of disease. (See",
"    <a class=\"local\" href=\"#H151472\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28935116\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent MN is suspected in the transplant patient who develops new and progressive proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated serum creatinine level. Indications for biopsy vary among transplant centers. We generally perform a biopsy in all transplant recipients with a history of MN who develop any persistent increase in protein excretion above baseline. The diagnosis of recurrent MN is made by classic findings of MN on renal biopsy. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H24#H24\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151472\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent disease can lead to loss of the allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/5,21,22\">",
"     5,21,22",
"    </a>",
"    ]. Estimates of the incidence of graft loss due to recurrent MN are provided by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 81 renal transplant recipients with MN on biopsy of their native kidney, the incidence of allograft loss at 10 years due to recurrent disease was 12.5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 28 kidney transplant patients, recurrent disease was associated with 10 percent risk of death-censored graft loss over 50 months of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151899\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for recurrent MN includes nonimmunosuppressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunosuppressive therapies. Our approach varies based upon the degree of proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with no or minimal protein excretion (ie, &lt;1",
"      <span class=\"nowrap\">",
"       g/d),",
"      </span>",
"      stable GFR, and only histologic evidence of recurrent MN (as detected for example by protocol biopsy) are managed with nonimmunosuppressive therapy alone. This primarily includes ACE inhibitor therapy and rigorous blood pressure control. We do not treat such patients with immunosuppressive therapies. It should be noted that proteinuria may increase with duration of disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/24\">",
"       24",
"      </a>",
"      ], so frequent reassessment is necessary.",
"     </li>",
"     <li>",
"      Patients with protein excretion &gt;1",
"      <span class=\"nowrap\">",
"       g/d",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a decreasing GFR are treated with both immunosuppressive and nonimmunosuppressive therapy. We prefer the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to the existing immunosuppressive regimen (with some modifications) rather than other immunosuppressive agents. Nonimmunosuppressive therapy principally consists of ACE inhibitor therapy and blood pressure control. (See",
"      <a class=\"local\" href=\"#H28935754\">",
"       'Moderate to severe disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28935777\">",
"    <span class=\"h3\">",
"     Mild disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with minimal protein excretion (eg, less than one",
"    <span class=\"nowrap\">",
"     gram/day),",
"    </span>",
"    stable renal function, and only histologic evidence of recurrent MN (as detected for example by protocol biopsy) have a reasonable prognosis if disease manifestations do not worsen over time. Such patients are only treated with nonimmunosuppressive therapy. Augmenting maintenance immunosuppressive therapy cannot be justified in such patients given the excellent prognosis in those in whom disease manifestations do not progress.",
"   </p>",
"   <p>",
"    Nonimmunosuppressive therapies for patients with recurrent mild MN include angiotensin inhibition, rigorous blood pressure control, and control of hyperlipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/11\">",
"     11",
"    </a>",
"    ]. Support for these interventions is derived from studies of nontransplanted patients with idiopathic MN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Nonimmunosuppressive therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No studies have conclusively demonstrated a benefit of angiotensin inhibition or good blood pressure control on the progression of recurrent MN in transplant recipients. In one small observational study of seven patients with recurrent MN, tight blood pressure control (with target of",
"    <span class=\"nowrap\">",
"     &lt;130/80",
"    </span>",
"    mmHg) and angiotensin inhibition did not prevent progression of proteinuria in six patients at eighteen months, although glomerular filtration rate remained stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/20\">",
"     20",
"    </a>",
"    ]. The optimal target blood pressure for patients who have had a renal transplantation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link&amp;anchor=H15#H15\">",
"     \"Hypertension after renal transplantation\", section on 'Definitions and goals of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28935754\">",
"    <span class=\"h3\">",
"     Moderate to severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with protein excretion greater than one",
"    <span class=\"nowrap\">",
"     gram/day",
"    </span>",
"    are given immunosuppressive therapy in addition to the nonimmunosuppressive therapies described above. (See",
"    <a class=\"local\" href=\"#H28935777\">",
"     'Mild disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rationale for this is based upon clinical experience as there are no well-designed studies to guide to the approach to the initiation of therapy for recurrent MN. The approach to immunosuppressive treatment of recurrent MN in the transplanted patient is different from that of nontransplanted patients who develop MN. As an example, nontransplanted patients who develop MN and who have only mild or moderate proteinuria are often not given immunosuppressive therapies because the rate of spontaneous remission is high. However, patients with recurrent MN are more likely to have aggressive disease since they have a history of end-stage renal disease due to MN, and since MN recurs despite immunosuppressive therapy to prevent rejection. Thus, patients with recurrent MN are generally treated more aggressively than those who present with MN for the first time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Indications for and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We prefer the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to the existing immunosuppressive regimen (with some modifications) rather than other immunosuppressive agents. Rituximab has been shown in limited studies to be effective for the treatment of recurrent MN. (See",
"    <a class=\"local\" href=\"#H152356\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other immunosuppressive agents have not been shown to be effective. The standard doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil used for immunosuppression after transplantation do not seem to protect against or change the course of recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. There are no rigorous studies that have examined the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    in recurrent MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/11\">",
"     11",
"    </a>",
"    ]. Single case reports of patients treated with cyclophosphamide have described contradictory results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Support for the use of cyclophosphamide is derived from studies of nontransplanted patients with idiopathic MN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small series and case reports that have studied the effect of glucocorticoids have yielded conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/2,25\">",
"     2,25",
"    </a>",
"    ]. In one small series, of three patients with recurrent MN who received high dose glucocorticoids, one had complete remission of nephrotic syndrome and one had a partial remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152356\">",
"    <span class=\"h4\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to the existing immunosuppressive regimen (with some modifications) for the treatment of moderate to severe recurrent MN. In case reports and limited series, rituximab induced remission of recurrent MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9,13,20,26-28\">",
"     9,13,20,26-28",
"    </a>",
"    ]. The best data are from the following two series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, eight patients with recurrent membranous nephropathy and protein excretion of approximately 4.5",
"      <span class=\"nowrap\">",
"       g/d",
"      </span>",
"      were given",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (two doses of one gram each given two weeks apart) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/20\">",
"       20",
"      </a>",
"      ]. By 12 months, six of eight patients had either complete (protein excretion &lt;250",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      or less) or partial (50 percent decrease in protein excretion) remission. By 24 months, six of seven patients had remissions and one patient had relapsed. Posttreatment biopsies showed at least partial resolution of histologic changes with resorption of electron dense immune deposits in six of seven patients and negative staining for C3 and IgG in four of seven and three of seven patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two patients were hospitalized with serious infections, including pneumonia and histoplasmosis.",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      stabilized or reduced proteinuria and stabilized GFR in four patients with recurrent MN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9\">",
"       9",
"      </a>",
"      ]. Two patients received 4 weekly doses of 375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      and two received 2 doses of 1 g with a two-week interval. Depletion of B cells was demonstrated in all patients.",
"     </li>",
"     <li>",
"      In one study of 8 patients with recurrent MN and protein excretion &gt;1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      reduced protein excretion in all patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is not known. The two small studies cited above used either two doses of 1000 mg given two weeks apart or 4 weekly doses of 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. However such dosing regimens may cause significant immunosuppression or other toxic effects among patients who are already on antiproliferative agents and glucocorticoids as part of an anti-rejection regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    effectively deplete B cells among renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. As an example, in one study, single doses of 200 mg of rituximab depleted B cells among fifty ABO-incompatible renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/31\">",
"     31",
"    </a>",
"    ]. However no studies have examined the effect of lower doses of rituximab for the treatment of recurrent MN in transplant patients.",
"   </p>",
"   <p>",
"    Given the absence of definitive studies, some clinicians give one dose of 200 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    whereas others give 1 to 4 doses of 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    with measurement of B cell CD19 after each administration. If the latter regimen is used, further rituximab dosing is stopped as soon as lymphocytes are undetectable.",
"   </p>",
"   <p>",
"    All other immunosuppressive therapies that are used to prevent rejection are continued among patients who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . We generally do not modify the doses of other immunosuppressive agents since the risk of leukopenia is low with rituximab. Infusion reactions are common with rituximab and may be prevented with premedication with antihistamines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with or without a glucocorticoid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link&amp;anchor=H12#H12\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Infusion reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    generally occurs within a few weeks. A response is best assessed by monitoring protein excretion and by measuring the percentage of CD19-B cells. Any consistent decrease in protein excretion is regarded as a positive response. Among patients who respond, the percentage of CD19 B positive cells generally decreases to less than one percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who have a decline in the CD19 B cell count to less than one percent but do not have a decrease in protein excretion,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be re-administered, but we generally wait until the CD19 B cell count increases to greater than one percent or proteinuria increases &gt;1 gram per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182142647\">",
"    <span class=\"h4\">",
"     Rituximab-resistant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among transplanted patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , cytotoxic agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be used for the treatment of recurrent MN. The doses are empiric and based upon data derived from studies of nontransplanted patients with idiopathic MN. We generally give 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of cyclophosphamide to patients who do not respond to rituximab. Patients who are started on cyclophosphamide should discontinue any antimetabolites that they are on (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ), though other antirejection medications, including calcineurin inhibitors and glucocorticoids may be continued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should be followed closely since it increases the risk of bone marrow suppression or malignancy in this high risk population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073579\">",
"    <span class=\"h1\">",
"     DE NOVO MEMBRANOUS NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;De novo MN may occur in patients who had end-stage renal disease due to a different primary renal disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/2,25,36-38\">",
"     2,25,36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117195306\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of de novo MN is approximately 1.5 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/21,25,39\">",
"     21,25,39",
"    </a>",
"    ]. However, the incidence increases with time after transplantation, and was 5.3 percent at eight years in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    De novo MN may be even more prevalent in children with renal transplants. In one report, de novo MN was present in 48 of 530 allograft biopsies in children (9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073586\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;De novo MN appears to be associated with chronic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibody-mediated rejection. Support for this association is provided by the renal biopsy which often shows signs of both rejection and the classic findings of MN, and by the presence of donor specific antibodies, which are characteristic of antibody-mediated rejection, in patients with de novo MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/37,38,40\">",
"     37,38,40",
"    </a>",
"    ]. In one study of five patients with de novo MN following transplantation, all five who were tested had donor specific antibodies at the time of biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast, donor-specific antibodies were not detected in any patients without MN in this study. Capillaritis and C4d deposition in the peritubular capillaries were common in the de novo MN group, even in those cases with undetectable donor specific antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/38\">",
"     38",
"    </a>",
"    ]. In another report, the titer of donor specific antibodies decreased in response to immunosuppressive therapy in one patient with de novo MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms underlying the association between de novo MN and rejection are unknown, although several theories have been proposed, all which focus on the excessive formation of antigen-antibody complexes at the glomerular basement membrane. As examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/25,38\">",
"     25,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rejection leads to exposure of previously undetected glomerular antigens leading to a humoral response.",
"     </li>",
"     <li>",
"      Circulating antibodies directed against HLA or other minor histocompatibility antigens expressed in the allograft predispose the recipient to both antibody-mediated rejection and de novo MN.",
"     </li>",
"     <li>",
"      Infections that occur in the setting of increased immunosuppression lead to the deposition of antigens in the glomerular basement membrane with subsequent antibody deposition.",
"     </li>",
"     <li>",
"      Rejection-mediated glomerular injury alters the glomerular basement membrane which facilitates the formation of subepithelial immune deposits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Host factors may also be important in the susceptibility of the individual to de novo MN. One small study reported a high incidence of recurrent MN (four out of seven) in patients who had a second transplant and a history of de novo MN in the first allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/36\">",
"     36",
"    </a>",
"    ]. In comparison, de novo MN was rare when the second transplant was performed in patients who did not have de novo MN in the first graft in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073593\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria due to de novo MN typically occurs many years after transplantation, which is a much later onset than that which characterizes recurrent MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. As examples, in two of the largest retrospective studies, the mean times from transplantation until biopsy diagnosis of de novo MN were 63 and 102 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] compared with 13 to 15 months noted among patients with recurrent MN. (See",
"    <a class=\"local\" href=\"#H152029\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many patients are asymptomatic and protein excretion remains in the subnephrotic range in approximately one-third or more of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117195337\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MN is made by classic findings of the disorder on renal biopsy. Determining whether MN in the allograft is recurrent or de novo requires an accurate diagnosis of the original cause of renal disease which may require reassessment of the native kidney biopsy when available.",
"   </p>",
"   <p>",
"    In addition, the renal biopsy often shows signs of both the findings of MN and rejection, and by the presence of donor specific antibodies, which are characteristic of antibody-mediated rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/37,38,40\">",
"     37,38,40",
"    </a>",
"    ]. Donor specific antibodies are found in 29 to 67 percent of cases of de novo MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/14,38\">",
"     14,38",
"    </a>",
"    ]. Evidence of transplant glomerulopathy, such as C4d staining in peritubular capillaries or duplication of glomerular basement membrane may indicate the additional presence of chronic antibody mediated rejection. The exact proportion of cases of de novo MN that have such additional features is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5139093\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of de novo MN is unclear. Although some small studies have reported a very poor outcome (50 percent graft loss), it is not known whether the loss was due to de novo MN and other concurrent factors, particularly chronic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibody mediated rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/25\">",
"     25",
"    </a>",
"    ]. As result, the optimal treatment of de novo MN in the transplanted patient is not known. In particular, it is not clear whether patients with de novo MN should be treated with additional immunosuppressive therapy, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or cytotoxic agents since no data have conclusively shown that de novo MN causes graft loss in the absence of other factors such as rejection.",
"   </p>",
"   <p>",
"    Our approach, which is based upon clinical experience, is determined by the degree of proteinuria that is present and on the stability of renal function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Due to the strong association of de novo MN and antibody-mediated rejection, when de novo MN is identified in this contest, the treatment of the rejection is paramount. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link\">",
"       \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We generally treat all patients with de novo MN with nonimmunosuppressive therapies as described above. (See",
"      <a class=\"local\" href=\"#H28935777\">",
"       'Mild disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We treat patients with protein excretion &lt;4",
"      <span class=\"nowrap\">",
"       g/d",
"      </span>",
"      and stable renal function with an increase in the maintenance dose of one or more components of the immunosuppressive regimen, though there are no are no good data that support this approach.",
"     </li>",
"     <li>",
"      We treat patients with protein excretion that is &ge;4",
"      <span class=\"nowrap\">",
"       g/d",
"      </span>",
"      or deteriorating renal function with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      as described above. (See",
"      <a class=\"local\" href=\"#H152356\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The standard use of calcineurin inhibitors for immunosuppression post-transplantation has not changed the incidence of de novo MN, and pulse therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    does not appear to lower protein excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34088/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , we treat with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or high dose alternate day glucocorticoids. Patients who are started on cyclophosphamide should discontinue any antimetabolites that they are on (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ), though other antirejection medications, including calcineurin inhibitors and glucocorticoids may be continued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasmapheresis may be considered among patients who have features of chronic rejection in addition to de novo MN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link&amp;anchor=H22#H22\">",
"     \"Chronic renal allograft nephropathy\", section on 'Summary immunosuppressive issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5139897\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membranous nephropathy (MN) may occur in the transplanted kidney, either as recurrent disease in patients who had MN as the initial cause of end stage renal disease in the native kidney or de novo in patients who originally had another cause of end stage renal disease. (See",
"      <a class=\"local\" href=\"#H26073572\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent MN typically presents 13 to 15 months after transplantation. Patients present with variable amounts of proteinuria that increase over time. Recurrent disease can lead to loss of the allograft. (See",
"      <a class=\"local\" href=\"#H152029\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H151472\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for recurrent MN includes nonimmunosuppressive and immunosuppressive therapies. Nonimmunosuppressive therapies include angiotensin inhibitors, rigorous blood pressure control, control of hyperlipidemia, and for select patients, anticoagulation. (See",
"      <a class=\"local\" href=\"#H28935777\">",
"       'Mild disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of idiopathic membranous nephropathy\", section on 'Nonimmunosuppressive therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limited data suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      is effective for the treatment of recurrent MN. The optimal dose of rituximab is not known. (See",
"      <a class=\"local\" href=\"#H152356\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with recurrent MN and protein excretion &gt;1",
"      <span class=\"nowrap\">",
"       g/d",
"      </span>",
"      we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than other therapies such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28935754\">",
"       'Moderate to severe disease'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Preferred rituximab dosing options include either one dose of 200 mg or 1 to 4 doses of 375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      with measurement of B cell CD19 after each administration. If the latter dose is used, further rituximab dosing is stopped as soon as lymphocytes are undetectable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All other immunosuppressive therapies that are used to prevent rejection may be continued among patients who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients have increasing protein excretion or a decline in kidney function despite",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H182142647\">",
"       'Rituximab-resistant'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients who are started on cyclophosphamide should stop any antimetabolites that they are on (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ), though other antirejection medications, including calcineurin inhibitors and glucocorticoids may be continued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      De novo MN may occur in transplant patients who developed end-stage renal disease due to a different primary renal disorder and is believed to be related to chronic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibody-mediated rejection. De novo MN generally occurs later than recurrent MN and proteinuria is often initially mild. However, graft loss associated with de novo MN is high although other factors such as chronic rejection contribute to the decline in renal function. (See",
"      <a class=\"local\" href=\"#H26073579\">",
"       'De novo membranous nephropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26073586\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26073593\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to the treatment of de novo MN is based upon the magnitude of proteinuria that is present and upon the stability of renal function (see",
"      <a class=\"local\" href=\"#H5139093\">",
"       'Treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All transplanted patients with de novo MN should be treated with nonimmunosuppressive therapies, as described for patients with recurrent MN.",
"     </li>",
"     <li>",
"      For transplanted patients with de novo MN who have protein excretion &lt;4",
"      <span class=\"nowrap\">",
"       g/d",
"      </span>",
"      and stable renal function we suggest augmentation of one or more components of their maintenance immunosuppressive regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For transplanted patients with de novo MN who have protein excretion &ge;4",
"      <span class=\"nowrap\">",
"       g/d",
"      </span>",
"      or deteriorating renal function, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      200 mg given once (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who do not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or high dose glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H182142647\">",
"       'Rituximab-resistant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/1\">",
"      Josephson MA, Spargo B, Hollandsworth D, Thistlethwaite JR. The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review. Am J Kidney Dis 1994; 24:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/2\">",
"      Berger BE, Vincenti F, Biava C, et al. De novo and recurrent membranous glomerulopathy following kidney transplantation. Transplantation 1983; 35:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/3\">",
"      Mathew TH. Recurrence of disease following renal transplantation. Am J Kidney Dis 1988; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/4\">",
"      Kotanko P, Pusey CD, Levy JB. Recurrent glomerulonephritis following renal transplantation. Transplantation 1997; 63:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/5\">",
"      Cosyns JP, Couchoud C, Pouteil-Noble C, et al. Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Clin Nephrol 1998; 50:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/6\">",
"      Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/7\">",
"      Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/8\">",
"      Dabade TS, Grande JP, Norby SM, et al. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant 2008; 8:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/9\">",
"      Sprangers B, Lefkowitz GI, Cohen SD, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010; 5:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/10\">",
"      Moroni G, Gallelli B, Quaglini S, et al. Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN). Nephrol Dial Transplant 2010; 25:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/11\">",
"      Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010; 5:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/12\">",
"      Obermiller LE, Hoy WE, Eversole M, Sterling WA. Recurrent membranous glomerulonephritis in two renal transplants. Transplantation 1985; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/13\">",
"      Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010; 363:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/14\">",
"      Debiec H, Martin L, Jouanneau C, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and&ensp;De Novo&ensp;membranous nephropathy. Am J Transplant 2011; 11:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/15\">",
"      Blosser CD, Ayalon R, Nair R, et al. Very early recurrence of anti-Phospholipase A2 receptor-positive membranous nephropathy after transplantation. Am J Transplant 2012; 12:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/16\">",
"      Debiec H, Hanoy M, Francois A, et al. Recurrent membranous nephropathy in an allograft caused by IgG3&kappa; targeting the PLA2 receptor. J Am Soc Nephrol 2012; 23:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/17\">",
"      Beck LH Jr. Monoclonal anti-PLA2R and recurrent membranous nephropathy: another piece of the puzzle. J Am Soc Nephrol 2012; 23:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/18\">",
"      Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/19\">",
"      Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/20\">",
"      El-Zoghby ZM, Grande JP, Fraile MG, et al. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009; 9:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/21\">",
"      Montagnino G, Colturi C, Banfi G, et al. Membranous nephropathy in cyclosporine-treated renal transplant recipients. Transplantation 1989; 47:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/22\">",
"      Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/23\">",
"      El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/24\">",
"      Rodriguez EF, Cosio FG, Nasr SH, et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am J Transplant 2012; 12:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/25\">",
"      Truong L, Gelfand J, D'Agati V, et al. De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature. Am J Kidney Dis 1989; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/26\">",
"      Gallon L, Chhabra D. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 2006; 6:3017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/27\">",
"      Weclawiak H, Ribes D, Guilbeau-Frugier C, et al. Relapse of membranous glomerulopathy after kidney transplantation: sustained remittance induced by rituximab. Clin Nephrol 2008; 69:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/28\">",
"      Sirimongkolrat T, Premasathian N, Vongwiwatana A, et al. Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report. Transplant Proc 2008; 40:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/29\">",
"      Cravedi P, Ruggenenti P, Remuzzi G. Low-dose rituximab for posttransplant recurrent membranous nephropathy. Am J Transplant 2010; 10:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/30\">",
"      Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/31\">",
"      Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/32\">",
"      Shirakawa H, Ishida H, Shimizu T, et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011; 25:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/33\">",
"      Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/34\">",
"      Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/35\">",
"      Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010; 5:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/36\">",
"      Heidet L, Gagnadoux ME, Beziau A, et al. Recurrence of de novo membranous glomerulonephritis on renal grafts. Clin Nephrol 1994; 41:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/37\">",
"      Schwarz A, Krause PH, Offermann G, Keller F. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. Transplantation 1994; 58:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/38\">",
"      Honda K, Horita S, Toki D, et al. De novo membranous nephropathy and antibody-mediated rejection in transplanted kidney. Clin Transplant 2011; 25:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/39\">",
"      Robles NR, Gomez-Campdera F, Anaya F, et al. Membranous glomerulonephritis after kidney transplantation and urologic complications. Am J Nephrol 1992; 12:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34088/abstract/40\">",
"      El Kossi M, Harmer A, Goodwin J, et al. De novo membranous nephropathy associated with donor-specific alloantibody. Clin Transplant 2008; 22:124.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7341 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34088=[""].join("\n");
var outline_f33_18_34088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5139897\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26073572\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H150862\">",
"      RECURRENT MEMBRANOUS NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151105\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150994\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152029\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28935116\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151472\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151899\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28935777\">",
"      - Mild disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28935754\">",
"      - Moderate to severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H152356\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H182142647\">",
"      Rituximab-resistant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26073579\">",
"      DE NOVO MEMBRANOUS NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117195306\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26073586\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26073593\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117195337\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5139093\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5139897\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=related_link\">",
"      C4d staining in renal allografts and treatment of antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39367?source=related_link\">",
"      IgA nephropathy: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32614?source=related_link\">",
"      Membranoproliferative glomerulonephritis: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_18_34089="Fused umbilical arteries";
var content_f33_18_34089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Fused umbilical arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panels A, B, and C) Fused umbilical arteries.",
"    <br>",
"     (Panel A) Simultaneous view of an umbilical cord with a fused umbilical artery. The segment closest to the placenta shows a two-vessel cord, while the segment closest to the fetus shows the normal three-vessel cord.",
"     <br>",
"      (Panel B) Dual view of the umbilical cord in a fetus with fused umbilical arteries shows a segment with three vessels (left) and two vessels (right). At delivery, the exact site at which the arteries fused is shown. The Wharton's jelly was removed after fixation with formalin.",
"      <br>",
"       (Panels D and E) Dual view of the umbilical cord from a fetus with fused umbilical cord. The umbilical cord has two vessels. However, the normal two intra-abdominal arteries are depicted with Color Doppler ultrasound.",
"       <div class=\"footnotes\">",
"        A: umbilical artery; V: umbilical vein.",
"       </div>",
"       <div class=\"reference\">",
"        Panels A, B, and C reproduced with permission from: Sepulveda W, Dezerega V, Carstens E, Gutierrez J. Fused umbilical arteries. Prenatal sonographic diagnosis and clinical significance. J Ultrasound Med 2001; 20:59. Copyright &copy; 2001 American Institute of Ultrasound in Medicine.",
"        <br/>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34089=[""].join("\n");
var outline_f33_18_34089=null;
var title_f33_18_34090="Approach to the patient with abnormal liver biochemical and function tests";
var content_f33_18_34090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with abnormal liver biochemical and function tests",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34090/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34090/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/18/34090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/18/34090/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/18/34090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The authors and editors at UpToDate would like express our gratitude to Marshall Kaplan who passed away in September 2012. Dr. Kaplan was an icon of Hepatology and a master clinician. He was the author of this and many other topic reviews. This topic review alone has contributed to the care of almost one-half a million patients each year. Dr. Kaplan cannot be replaced, but we will strive to maintain all of his topics to his high standards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review will provide an overview on the evaluation of patients with abnormal liver biochemical and function tests. Detailed discussions on the individual tests and patterns of abnormalities are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/63/21494?source=see_link\">",
"     \"Liver biochemical tests that detect injury to hepatocytes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for the evaluation of liver chemistry tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the term \"liver function tests\" (LFTs) is used commonly, it is imprecise since many of the tests reflecting the health of the liver are not direct measures of its function. Furthermore, the commonly used liver biochemical tests may be abnormal even in patients with a healthy liver.",
"   </p>",
"   <p>",
"    The most common laboratory measures classified as LFTs include the enzyme tests (principally the serum aminotransferases, alkaline phosphatase, and gamma glutamyl transpeptidase), tests of synthetic function (principally the serum albumin concentration and prothrombin time), and the serum bilirubin, which measures the liver's ability to detoxify metabolites and transport organic anions into bile.",
"   </p>",
"   <p>",
"    By convention, the abbreviation \"LFTs\" will be used to denote these tests throughout this discussion unless particular tests are specified. There are two aminotransferases: alanine aminotransferase (ALT, formerly called SGPT), and aspartate aminotransferase (AST, formerly called SGOT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal LFTs are frequently detected in asymptomatic patients since many screening test panels now routinely include them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/2\">",
"     2",
"    </a>",
"    ]. A population-based survey in the United States conducted between 1999 and 2002 estimated that an abnormal ALT was present in 8.9 percent of respondents (representing a significant increase compared with results of a similar survey from a decade earlier) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/3\">",
"     3",
"    </a>",
"    ]. This may be related to the increase in obesity that has also occurred during this same time period. The serum ALT level correlates with body mass index (BMI) and waist circumference, and the BMI of Americans has increased significantly over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating the clinical significance of these abnormalities have produced variable findings, although most have demonstrated that serious underlying liver disease is uncommon. The differences among individual studies reflect variation in the prevalence of liver disease in the populations that have been studied and the degree to which an underlying cause of the abnormalities was sought. Advances in the noninvasive tests to identify the cause of liver disease have permitted a greater understanding of the spectrum of liver disease encountered in various patient populations.",
"   </p>",
"   <p>",
"    The following examples illustrate some of the findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal serum aminotransferase levels (ALT &gt;2.25 SD above normal; &gt;55 int.",
"      <span class=\"nowrap\">",
"       unit/L)",
"      </span>",
"      were detected in 99 of 19,877 (0.5 percent) Air Force recruits beginning basic training [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/7\">",
"       7",
"      </a>",
"      ]. Of these, a cause was found in only 12 (including chronic hepatitis B and C, autoimmune hepatitis, and cholelithiasis). No specific diagnosis was established in the remaining 87 patients.",
"     </li>",
"     <li>",
"      The diagnoses observed in two studies that included a total of 249 blood donors with abnormal serum ALT values included [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]: alcoholic liver disease (11 to 48 percent); fatty liver (22 to 56 percent); hepatitis C (17 to 20 percent); miscellaneous causes (4 to 8 percent); and no specific diagnosis (2 to 9 percent). Similar results were seen in a study of 1118 adult primary care patients in the United Kingdom [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/10\">",
"       10",
"      </a>",
"      ]. Nonalcoholic fatty liver disease was the most common diagnosis (26 percent), followed by alcoholic liver disease (25 percent). However, unlike the blood donor studied, many more patients had elevations that were unexplained (45 percent) despite an evaluation that included ultrasonography and tests for viral, genetic, and autoimmune causes.",
"     </li>",
"     <li>",
"      Another study focused on 81 of 1124 patients who were referred for abnormal serum aminotransferase levels in whom a diagnosis could not be inferred noninvasively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/11\">",
"       11",
"      </a>",
"      ]. A liver biopsy revealed steatosis or steatohepatitis in the majority of patients (84 percent); six patients had fibrosis or cirrhosis, and eight had normal histologic findings. Steatosis was also common in a study of 354 patients who underwent a liver biopsy to investigate abnormal LFTs (defined as an ALT, gamma glutamyl transpeptidase (GGT), or alkaline phosphatase more than twice the upper limit of normal for at least six months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/12\">",
"       12",
"      </a>",
"      ]. Patients with clinical or serologic features suggesting a specific diagnosis were excluded. The most frequent finding on liver biopsy was nonalcoholic steatohepatitis or fatty liver (66 percent). The authors considered information from the biopsy results to be important for directing management in 18 percent of patients. In addition, three families were entered into screening programs for heritable liver disease.",
"     </li>",
"     <li>",
"      A population-based study from the United States evaluated the impact of an elevated GGT and ALT on overall mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/13\">",
"       13",
"      </a>",
"      ]. An elevated GGT was associated with a modestly increased mortality from all causes (Hazard Ratio (HR), 1.5; 95% CI, 1.2-1.8), liver disease, cancer, and diabetes mellitus, while an elevated ALT was associated only with an increase in liver-related mortality (HR, 8.2; 95% CI, 2.1-31.9). However, these observations do not alter the approach to patients with abnormal liver biochemical tests described in this topic review.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several conclusions can be derived from the above observations. First, most studies show that a diagnosis can be established noninvasively in the vast majority of patients with abnormal LFTs. Second, appropriate testing can be guided by the pretest probability of specific forms of liver disease. Third, the majority of patients in whom the diagnosis remains unclear after obtaining a history and laboratory testing will have alcoholic liver disease, steatosis, or steatohepatitis. Finally, on a population-level, abnormal liver biochemical tests may be a marker for worse health outcomes.",
"   </p>",
"   <p>",
"    It is important to emphasize that false positive results are more likely in patients who have a low pretest probability of having liver disease. This is a particular concern when abnormal LFTs are detected as part of a panel of laboratory tests drawn for other reasons. Normal test reference values are usually arbitrarily defined as those occurring within two standard deviations from the mean. As a result, 5 percent of healthy individuals who have a single screening test will have an abnormal result (2.5 percent will have an abnormally high result). As more tests are ordered, the likelihood of a false positive test increases; a screening panel containing 20 independent tests in a patient with no disease will yield at least one abnormal result 64 percent of the time (",
"    <a class=\"graphic graphic_table graphicRef60009 \" href=\"mobipreview.htm?3/52/3915\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, individual patients can have baseline fluctuation in serum aminotransferase levels. In a large, cross-sectional population-based study, more than 30 percent of adults with abnormal LFTS were reclassified as being normal upon retesting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/14\">",
"     14",
"    </a>",
"    ]. The study did not examine whether these patients had underlying liver disease but supports confirming abnormal test results. It is also noteworthy that initiation of a high-fat diet can lead to often transient aminotransferase elevations.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of the serum aminotransferases (particularly serum ALT) for discriminating those with and without liver disease depends upon the cutoff values chosen to define an abnormal test. A population-based study from the US National Health and Nutrition Examination Survey examined patients with known HCV infection (n=259) and compared them with patients at low risk of liver injury (n=3747) to determine optimal cutoff values for ALT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/15\">",
"     15",
"    </a>",
"    ]. An ALT cutoff of 29 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    for men had the highest degree of correct classification, with a sensitivity of 88 percent and a specificity of 83 percent (area under the receiver operating characteristic curve [AUC] 9.3). For women, the cutoff was 22 int.",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    with a sensitivity of 89 percent and a specificity of 82 percent (AUC 0.92). By applying these cutoffs to the entire population (n=18,518), 36 percent of men and 28 percent of women would be classified as having an elevated ALT.",
"   </p>",
"   <p>",
"    ALT levels correlate with the degree of trunk fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/16\">",
"     16",
"    </a>",
"    ], and at least two large studies suggested that the cutoff values should be adjusted for gender and BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, most patients identified with the lower cutoff values had only mild liver disease or no identifiable cause of the abnormal laboratory values. Thus, the overall benefit of the proposed modifications is unclear since it would translate into a large increase in the absolute numbers of patients who would require evaluation for an uncertain clinical benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another consideration is that there is wide variability of what is considered to be the upper limit of normal for ALT across different laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/18\">",
"     18",
"    </a>",
"    ]. This is likely due to the references used for different chemical analyzers. Thus, comparing values across different laboratories may not be straightforward. In addition, cutoff levels for recognition of liver disease differ based on the reference used at the specific laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete medical history is the single most important part of the evaluation of the patient with elevated LFTs. Important considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of or exposure to any chemical or medication (including prescription and over-the-counter medications as well as herbal remedies) that may be temporally related to the onset of LFT abnormalities",
"     </li>",
"     <li>",
"      The duration of LFT abnormalities",
"     </li>",
"     <li>",
"      The presence of any accompanying symptoms such as jaundice, arthralgias, myalgias, rash, anorexia, weight loss, abdominal pain, fever, pruritus, and changes in the color of urine and stool",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although none of the latter symptoms is specific for any one condition, an associated finding may suggest a particular diagnosis and help guide further testing. A history of arthralgias and myalgias predating jaundice, for example, suggests viral or drug-related hepatitis, while jaundice associated with the sudden onset of severe right upper quadrant pain and shaking chills suggests choledocholithiasis and ascending cholangitis.",
"   </p>",
"   <p>",
"    The patient should also be questioned carefully about possible parenteral exposures including transfusions, intravenous and intranasal drug use, tattoos, and sexual activity. Other important questions include recent travel history, exposure to people with jaundice, exposure to possibly contaminated foods, occupational exposure to hepatotoxins, and alcohol consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should focus upon findings suggesting the presence of liver disease. Specific findings may provide clues toward diagnosis of an underlying cause.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporal and proximal muscle wasting suggests a longstanding disease",
"     </li>",
"     <li>",
"      Stigmata of chronic liver disease include spider nevi, palmar erythema, gynecomastia, and caput medusae",
"     </li>",
"     <li>",
"      Dupuytren's contractures, parotid gland enlargement, and testicular atrophy are commonly seen in advanced Laennec's cirrhosis and occasionally in other types of cirrhosis",
"     </li>",
"     <li>",
"      An enlarged left supraclavicular node (Virchow's node) or periumbilical nodule (Sister Mary Joseph's nodule) suggest an abdominal malignancy",
"     </li>",
"     <li>",
"      Increased jugular venous pressure, a sign of right-sided heart failure, suggests hepatic congestion",
"     </li>",
"     <li>",
"      A right pleural effusion, in the absence of clinically apparent ascites, may be seen in advanced cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The abdominal examination should focus on the size and consistency of the liver, the size of the spleen (a palpable spleen is enlarged), and an assessment for ascites (usually by determining whether there is a fluid wave, shifting dullness, or bulging of the flanks). Patients with cirrhosis may have an enlarged left lobe of the liver (which can be felt below the xiphoid) and an enlarged spleen (which is most easily appreciated with the patient in the right lateral decubitus position). A grossly enlarged nodular liver or an obvious abdominal mass suggests malignancy. An enlarged tender liver could be due to viral or alcoholic hepatitis or, less often, an acutely congested liver secondary to right-sided heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/19\">",
"     19",
"    </a>",
"    ]. Severe right upper quadrant tenderness with respiratory arrest on inspiration (Murphy's sign) suggests cholecystitis or, occasionally, ascending cholangitis. Ascites in the presence of jaundice suggests either cirrhosis or malignancy with peritoneal spread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical step in guiding the evaluation is determining the overall pattern of the abnormal LFTs, which can be broadly divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A pattern predominantly reflecting hepatocellular injury",
"     </li>",
"     <li>",
"      A pattern predominantly reflecting cholestasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a hepatocellular process generally have a disproportionate elevation in the serum aminotransferases compared with the alkaline phosphatase, while those with a cholestatic process have the opposite findings. The serum bilirubin can be prominently elevated in both hepatocellular and cholestatic conditions and therefore is not necessarily helpful in differentiating between the two. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/63/21494?source=see_link\">",
"     \"Liver biochemical tests that detect injury to hepatocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum albumin level and a prothrombin time should be obtained to assess liver function. A low albumin suggests a chronic process such as cirrhosis or cancer, while a normal albumin suggests a more acute process such as viral hepatitis or choledocholithiasis. A prolonged prothrombin time indicates either vitamin K deficiency due to prolonged jaundice and intestinal malabsorption of vitamin K or significant hepatocellular dysfunction. The failure of the prothrombin time to correct with parenteral administration of vitamin K indicates severe hepatocellular injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of bilirubin in the urine reflects direct hyperbilirubinemia and therefore underlying hepatobiliary disease. In contrast to conjugated bilirubin, unconjugated bilirubin is tightly bound to albumin; as a result, it is neither filtered by the glomerulus nor present in the urine unless there is underlying renal disease.",
"   </p>",
"   <p>",
"    Conjugated bilirubin may be found in the urine when the total serum bilirubin concentration is normal because the renal reabsorptive capacity for conjugated bilirubin is low and the methods used can detect urinary bilirubin concentrations as low as 0.05",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Thus, bilirubinuria may be an early sign of liver disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36294?source=see_link\">",
"     \"Clinical aspects of serum bilirubin determination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMMON PATTERNS OF LFT ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus on the cost-effective approach to the evaluation of patients with abnormal LFTs has not been established. Thus, the decision to pursue specific testing should be guided by the pretest probability of the underlying liver disease, the pattern of abnormalities, and suggestive features obtained from the history and physical examination. The following sections will provide recommendations for the initial evaluation of patients with common patterns of LFT abnormalities. The recommendations are based upon the epidemiology and clinical features of the various disorders, the accuracy of diagnostic testing, and clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MILD CHRONIC ELEVATION IN SERUM AMINOTRANSFERASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of patients with chronic (defined as six months or greater), mild elevation (defined approximately as less than five times the upper limit of normal) of one or both of the aminotransferases is best achieved in a stepwise fashion to eliminate unnecessary testing. On the other hand, it is sometimes convenient for patients (particularly in the referral setting) if several blood tests are obtained simultaneously since they can be processed on the same sample, thereby eliminating a return visit for additional testing. Furthermore, the order of the testing may change if the history and physical examination raise the pretest probability of a particular diagnosis. Thus, the steps outlined below are meant to be general guidelines (",
"    <a class=\"graphic graphic_table graphicRef68475 \" href=\"mobipreview.htm?26/33/27164\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The approach to patients with marked elevations in serum aminotransferases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Step one",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step should be to identify medications and supplements that can cause elevation of the serum aminotransferases, to assess for alcohol use, and to test for viral hepatitis B and C, hemochromatosis, and fatty liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost any medication can cause an elevation of liver enzymes. Common causes include nonsteroidal anti-inflammatory drugs, antibiotics, statins, antiepileptic drugs, and antituberculous drugs. In addition, herbal preparations and illicit drug use may also be the cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Questioning should also include nonprescription medications;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , for example, can cause transient aminotransferase elevation among healthy adults even when taken in recommended doses. In a study of healthy volunteers taking acetaminophen (4 g daily for 14 days), about 20 percent experienced an ALT elevation more than five times the upper limit of normal (compared with 3 percent taking placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/20\">",
"     20",
"    </a>",
"    ]. An increase of 1 to 2 times the upper limit of normal was observed in 50 to 70 percent of patients. Elevation was not observed before three days of administration and generally resolved despite continued use of acetaminophen.",
"   </p>",
"   <p>",
"    A careful history and review of laboratory data are critical for identifying a medication as the cause of elevated serum aminotransferases. However, the diagnosis of drug-induced liver injury can be difficult. The relationship to drug ingestion and toxicity is not always clear; patients may be taking multiple medications, making identification of the offending agent difficult, and the development of abnormal LFTs can occasionally be delayed, obscuring its relationship to hepatotoxicity. In addition, patients may have concomitant diseases (such as alcoholism), which can produce similar clinical and laboratory abnormalities.",
"   </p>",
"   <p>",
"    Features suggesting drug toxicity include lack of illness prior to ingesting the drug, clinical illness or biochemical abnormalities developing after beginning the drug, and improvement after the drug is withdrawn. If an immunologic reaction is suspected, the illness will generally recur upon reintroduction of the offending substance. However, rechallenge is not advised.",
"   </p>",
"   <p>",
"    If the identified medication is essential to the patient's well-being and no suitable substitute is available, the clinician needs to make a risk-benefit analysis to determine if a drug should be continued despite the aminotransferase elevation. A liver biopsy is occasionally necessary to determine the nature and severity of liver injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Alcohol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of alcohol abuse can be difficult because many patients conceal this information. Several short questionnaires are of assistance in detecting occult alcohol abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .) The diagnosis of alcoholic liver disease is supported by an AST to ALT ratio of 2:1 or greater. In a study of hundreds of patients who had liver biopsy-confirmed liver disorders, more than 90 percent of the patients whose AST to ALT ratio was two or greater had alcoholic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/21\">",
"     21",
"    </a>",
"    ]. The percentage increased to greater than 96 percent when the ratio was greater than three. However, subsequent studies have revealed that the",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio may also be occasionally elevated in an alcoholic liver disease pattern in patients with nonalcoholic steatohepatitis and is frequently elevated in an alcoholic liver disease pattern in patients with hepatitis C who have developed cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other patterns of laboratory abnormalities may also be supportive of the diagnosis of alcoholic liver disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A twofold elevation of the GGT in patients whose AST to ALT ratio is greater than 2:1 strongly suggests alcohol abuse. However, an elevated GGT by itself is insufficiently specific to establish the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"       \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is rare for the AST to be greater than eightfold elevated and even less common for the ALT to be greater than fivefold elevated. The ALT may even be normal even in patients with severe alcoholic liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretest probability for hepatitis B is increased in patients with a history of parenteral exposures and in patients from parts of the world where high disease prevalence exists (eg, in Southeast Asia, China, and sub-Saharan Africa). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proper initial testing for patients suspected of having chronic hepatitis B includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatitis B surface antigen (HBsAg)",
"     </li>",
"     <li>",
"      Hepatitis B surface antibody (anti-HBs)",
"     </li>",
"     <li>",
"      Hepatitis B core antibody (anti-HBc)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are surface antigen and core antibody positive are chronically infected and additional testing (hepatitis B \"e\" antigen and \"e\" antibody and a hepatitis B DNA [HBV DNA]) is indicated. Positive anti-HBs and anti-HBc indicate immunity to hepatitis B, and another cause of aminotransferase elevation should be sought. The presence of HBV DNA in the presence or absence of the hepatitis B e antigen indicates viral replication. The presence of HBV DNA and a negative hepatitis B e antigen generally indicates that the patient has a mutation in the precore region of HBV. Both of these situations warrant further evaluation with a liver biopsy and possible treatment. A positive HBsAg with a negative HBV DNA and a negative hepatitis B e antigen suggests that the patient is an inactive carrier of HBV. The presence of the carrier state does not explain elevated aminotransferases, and another cause needs to be sought. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hepatitis C is common in the United States and other parts of the world. The risk is highest in individuals with a history of parenteral exposure (blood transfusions, intravenous drug use, occupational), cocaine use, tattoos, body piercing, and high risk sexual behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The actual sequence of diagnostic testing in an individual patient depends upon the clinical setting. Initial evaluation typically begins with a hepatitis C antibody and, if positive, hepatitis C viral RNA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link&amp;anchor=H25#H25\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemochromatosis is a common genetic disorder. Population screening has shown that the frequency of heterozygotes for the",
"    <em>",
"     HFE",
"    </em>",
"    gene mutation",
"    <em>",
"     C282Y",
"    </em>",
"    is about 10 percent in Caucasian populations in the United States and western Europe, with a frequency of about 5 per 1000 (0.5 percent) for the homozygous state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for hemochromatosis should begin with a serum iron and total iron binding capacity (TIBC), which permits the calculation of the iron or transferrin saturation (serum",
"    <span class=\"nowrap\">",
"     iron/TIBC).",
"    </span>",
"    An iron saturation of greater than 45 percent warrants obtaining a serum ferritin. Ferritin should not be obtained as an initial test because it is an acute phase reactant and therefore less specific than the iron saturation. A serum ferritin concentration of greater than 400",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in men and 300",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in women further supports the diagnosis of hemochromatosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic testing should be done in a person with evidence of iron overload. Liver biopsy may be considered particularly in patients with a",
"    <em>",
"     C282Y",
"    </em>",
"    homozygous or",
"    <span class=\"nowrap\">",
"     <em>",
"      C282Y",
"     </em>",
"     /",
"     <em>",
"      H63D",
"     </em>",
"    </span>",
"    genotype and a serum ferritin &ge;1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    to determine if cirrhosis is present or in patients with iron overload but negative genetic testing. A hepatic iron index (hepatic iron concentration in micromoles per gram dry weight divided by the patient's age) greater than 1.9 is consistent with hemochromatosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=see_link\">",
"     \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"    </a>",
"    .) A liver biopsy is",
"    <strong>",
"     not",
"    </strong>",
"    necessary for patients with genotypically defined hemochromatosis, normal liver biochemical tests, and a serum ferritin &lt;1000",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Not every patient who is homozygous for the",
"    <em>",
"     HFE",
"    </em>",
"    mutation has iron overload, and not every patient with hemochromatosis has the identified",
"    <em>",
"     HFE",
"    </em>",
"    mutation. Thus, liver biopsy may still be required to identify iron overload in some patients and is critical to determine the amount of fibrosis as noted above. Patients with hemochromatosis and cirrhosis continue to have a high risk of developing hepatocellular carcinoma even after depletion of body iron stores. These patients need to be identified and screened appropriately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hepatic steatosis and steatohepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic steatosis and an associated condition, nonalcoholic steatohepatitis (NASH), may present solely with mild elevations of the serum aminotransferases, which are usually less than fourfold elevated. NASH is more common in women than men and associated with obesity, type 2 diabetes mellitus, and hypertriglyceridemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .) In contrast to alcohol-related liver disease, the ratio of AST to ALT is usually less than one.",
"   </p>",
"   <p>",
"    The initial evaluation to identify the presence of fatty infiltration of the liver is radiologic imaging including ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI). Ultrasonography has a lower sensitivity than CT or MRI, but is less expensive. Thus, in a patient in whom there is a high pretest probability of steatosis and tests for hepatitis B, C, and hemochromatosis are unremarkable, the least expensive test to look for steatosis is ultrasonography. However, radiologic imaging cannot identify inflammation. Thus, the differentiation between steatosis and NASH requires a liver biopsy. Nevertheless, because of the absence of effective medical therapy for NASH, we do not advocate a liver biopsy unless one of the following is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral stigmata of chronic liver disease",
"     </li>",
"     <li>",
"      Splenomegaly",
"     </li>",
"     <li>",
"      Cytopenia",
"     </li>",
"     <li>",
"      Abnormal iron studies",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant obesity in an individual over the age of 45",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Step two",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the aforementioned causes of aminotransferase elevations are excluded, the next set of tests should look for non-hepatic causes of elevated aminotransferases, which include principally muscle disorders, thyroid disease, celiac disease, and rarely adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Muscle disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum aminotransferases may be caused by disorders that affect organs other than the liver, most commonly striated muscle. Serum AST and ALT may both be elevated with muscle injury. Their ratio depends in part upon when they are assessed relative to the muscle injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/23\">",
"     23",
"    </a>",
"    ]. Immediately after muscle injury, the",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio is generally greater than three but approaches one within a few days because of a faster decline in the serum AST. Peak AST and ALT levels are variable. In one series, peak AST levels range from as low as 235 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    to as high as 10,000 int.",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    while peak ALT ratios range from as low as 115 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    to as high as 850 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conditions that can cause muscle injury include subclinical inborn errors of muscle metabolism, acquired muscle disorders (such as polymyositis), seizures, and heavy exercise (such as long distance running). If striated muscle is the source of increased aminotransferases, serum levels of creatine kinase, lactate dehydrogenase (LDH), and aldolase will be elevated at least to the same degree. The creatine kinase or aldolase levels should be determined if other more common hepatic conditions have been ruled out (",
"    <a class=\"graphic graphic_table graphicRef68475 \" href=\"mobipreview.htm?26/33/27164\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Thyroid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid disorders can produce elevated aminotransferases by unclear mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. An assay for thyroid stimulating hormone (TSH) is a reasonable screening test for hypothyroidism, while a full set of thyroid function tests should be checked if hyperthyroidism is suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described elevated serum aminotransferases in patients with undiagnosed celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/26\">",
"     26",
"    </a>",
"    ]. The cause is uncertain. In one report, the serum AST ranged from 29 to 80, and the serum ALT ranged from 60 to 130, with the ALT usually slightly greater than AST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/27\">",
"     27",
"    </a>",
"    ]. Serum aminotransferases returned to normal in all but one patient one year following a gluten free diet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H31#H31\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of celiac disease is suggested by appropriate antibody screening with serum IgA antiendomysial or IgA transglutaminase antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminotransferase elevation (1.5 to 3 times the upper limit of normal) has been described in patients with adrenal insufficiency (due to Addison's disease or secondary causes), including those without obvious clinical features of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Aminotransferase levels normalize within one week following appropriate treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa has been associated with aminotransferase elevation by mechanisms that are not well understood. In a series of 214 women, 12 percent had aminotransferase elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/31\">",
"     31",
"    </a>",
"    ]. In another series, elevated serum aminotransferases were associated with a lower body temperature and pulse rate and a lower BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/32\">",
"     32",
"    </a>",
"    ]. Profound serum aminotransferase elevation associated with liver dysfunction has been described in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Step three",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next set of tests is aimed at identifying less common liver conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis (AIH) is a condition found primarily in young to middle-aged women. The diagnosis is based upon the presence of elevated serum aminotransferases, the absence of other causes of chronic hepatitis, and features (serologic and pathological) suggestive of AIH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A useful screening test for AIH is the serum protein electrophoresis (SPEP). More than 80 percent of patients with autoimmune hepatitis have hypergammaglobulinemia. A greater than twofold polyclonal elevation of the immunoglobulins supports the diagnosis. Additional tests commonly ordered include antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and liver-kidney type 1 microsomal antibodies (LKMA). ANA and SMA have reported sensitivities of up to 70 percent. LKMA-positive autoimmune hepatitis is seen primarily in Europe and is rare in the United States, Australia, and Japan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reasonable approach to diagnosing autoimmune hepatitis is to start with an SPEP. An ANA and SMA should be obtained in patients who have a polyclonal increase in gamma globulin. Elevated gamma globulins and high-titer autoantibodies should prompt a liver biopsy to confirm the diagnosis of AIH. Patients (especially young women) with negative viral serologies and persistently elevated aminotransferase levels greater than 100 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    should undergo liver biopsy even in the absence of elevated gamma globulin levels and autoantibodies. If the biopsy is consistent with chronic hepatitis, patients should receive a trial of corticosteroids since approximately 20 percent of patients with steroid-responsive hepatitis will not have a positive ANA or SMA at the time of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Wilson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease, a genetic disorder of biliary copper excretion, may cause elevated aminotransferases in asymptomatic patients. While the prevalence of Wilson disease is very low, it is a treatable liver disease and needs to be identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients usually present between ages 5 and 25 years, but the diagnosis should be considered in patients up to the age of 40 years and occasionally older; the range of ages in case reports spans from age 3 to 80 years. The initial screening test for Wilson disease is a serum ceruloplasmin level, which will be reduced in approximately 85 percent of patients. Patients should also be examined by an ophthalmologist for Kayser-Fleischer rings. If the ceruloplasmin is normal and Kayser-Fleischer rings are absent, but there is still a suspicion of Wilson disease, the next test is a 24-hour urine collection for quantitative copper excretion. A value greater than 100",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    is suggestive of the diagnosis. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is usually confirmed by a liver biopsy for quantitative copper. Patients with Wilson disease have liver copper levels greater than 250",
"    <span class=\"nowrap\">",
"     mcg/gm",
"    </span>",
"    dry weight of liver. Although the gene responsible for Wilson disease has been identified, the number of disease-specific mutations is so great (&gt;300) that molecular diagnosis is not often feasible except in family members of a proband with a known mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Alpha-1 antitrypsin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-1 antitrypsin deficiency is an uncommon cause of chronic liver disease in adults. Decreased levels of alpha-1 antitrypsin in serum can be detected either by direct measurement of serum concentrations or by the absence of the alpha-1 peak on a serum protein electrophoresis. However, serum concentrations of alpha-1 antitrypsin can be increased in response to inflammation, thereby resulting in a falsely negative result. Therefore, obtaining an alpha-1 antitrypsin phenotype is probably the most cost-effective test. In adults, alpha-1 antitrypsin deficiency should be suspected in patients who have a history of emphysema either at a young age or out of proportion to their smoking history. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=see_link\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936652365\">",
"    <span class=\"h3\">",
"     Adult bile ductopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult bile ductopenia is a rare inherited condition that presents with elevated aminotransferase levels. In mild forms, patients are asymptomatic, while in more serious forms, patients have pruritus and elevations of alkaline phosphatase levels. The diagnosis is based upon liver biopsy findings. In the healthy liver, there are approximately 1.5 to 2 bile ducts cut in cross section per portal triad. In adult bile ductopenia, there are typically fewer than 1.2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21128?source=see_link\">",
"     \"Hepatic ductopenia and vanishing bile duct syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients respond to treatment with ursodeoxycholic acid (12 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight orally per day). Such patients have normalization of the serum aminotransferases and generally do not progress to cirrhosis. By contrast, in the severe form, the disease progresses despite treatment, and patients may eventually require liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Step four",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver biopsy is often considered in patients in whom all of the above testing has been unrevealing. However, in some settings, the best course may be expectant observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Whom to observe",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend observation only in patients in whom the ALT and AST levels are less than twofold elevated and no chronic liver condition has been identified by the above noninvasive testing. This approach was supported by a preliminary study in which expectant clinical follow-up was found to be the most cost-effective strategy for managing asymptomatic patients with negative viral, metabolic, and autoimmune markers and chronically elevated aminotransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/38\">",
"     38",
"    </a>",
"    ]. Another study included 36 patients with a chronic elevation of the serum ALT, AST, or alkaline phosphatase (50 percent or greater above normal) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with a strong suspicion for a particular liver disease were excluded. The remainder underwent a liver biopsy, which changed the diagnosis in only 5 patients and influenced treatment in 12 patients, 10 of whom were offered investigational therapy. The authors concluded that the biopsy results only infrequently clarified the presumptive diagnosis and that no proven therapy exists for many such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Whom to biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a liver biopsy in patients in whom the ALT and AST are persistently greater than twofold elevated. While it remains unlikely that the biopsy will provide a diagnosis or lead to changes in management, it is often reassuring to the patient and clinician to know that there is no serious disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ISOLATED HYPERBILIRUBINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated hyperbilirubinemia occurs principally in two settings (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overproduction of bilirubin",
"     </li>",
"     <li>",
"      Impaired uptake, conjugation, or excretion of bilirubin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial step in evaluating a patient with an isolated elevated hyperbilirubinemia is to fractionate the bilirubin to determine whether the hyperbilirubinemia is predominantly conjugated or unconjugated. An increase in unconjugated bilirubin in serum results from either overproduction, impairment of uptake, or impaired conjugation of bilirubin. An increase in conjugated bilirubin is due to decreased excretion into the bile ductules or leakage of the pigment from hepatocytes into serum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36294?source=see_link\">",
"     \"Clinical aspects of serum bilirubin determination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Unconjugated hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect hyperbilirubinemia may be observed in a number of disorders (",
"    <a class=\"graphic graphic_table graphicRef55607 \" href=\"mobipreview.htm?27/55/28541\">",
"     table 3",
"    </a>",
"    ). These can be divided into disorders associated with bilirubin overproduction (such as hemolysis and ineffective erythropoiesis) and disorders related to impaired hepatic",
"    <span class=\"nowrap\">",
"     uptake/conjugation",
"    </span>",
"    of bilirubin (such as Gilbert's disease, Crigler-Najjar syndrome, and the effects of certain drugs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis can usually be detected by obtaining a reticulocyte count and haptoglobin and examining the peripheral smear. Hemolytic disorders that cause excessive heme production may be either inherited or acquired. Inherited disorders include spherocytosis, sickle cell disease, and deficiency of red cell enzymes such as pyruvate kinase and glucose-6-phosphate dehydrogenase. In these conditions, the serum bilirubin rarely exceeds 5",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Higher levels may occur when there is coexistent renal or hepatocellular dysfunction or acute hemolysis such as a sickle cell crisis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquired hemolytic disorders include microangiopathic hemolytic anemia (eg, hemolytic-uremic syndrome), paroxysmal nocturnal hemoglobinuria, and immune hemolysis. Ineffective erythropoiesis occurs in cobalamin, folate, and iron deficiencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Impaired hepatic uptake or conjugation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired hepatic uptake or conjugation of bilirubin should be considered in the absence of hemolysis. This is most commonly caused by certain drugs (including rifampicin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    ), which diminish hepatic uptake of bilirubin, or Gilbert's syndrome (a common genetic disorder associated with unconjugated hyperbilirubinemia). Much less commonly, indirect hyperbilirubinemia can be caused by two other genetic disorders: Crigler-Najjar syndrome types I and II.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gilbert's syndrome affects approximately 3 to 7 percent of the population, with white males predominating over females by a ratio of 2 to 7:1. Impaired conjugation of bilirubin is due to reduced bilirubin uridine diphosphate (UDP) glucuronosyltransferase activity. Affected patients have mild unconjugated hyperbilirubinemia with serum levels almost always less than 6",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      The serum levels may fluctuate, and jaundice is often identified only during periods of illness or fasting. In an otherwise healthy adult with mildly elevated unconjugated hyperbilirubinemia and no evidence of hemolysis, the presumptive diagnosis of Gilbert's syndrome can be made without further testing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"       \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Crigler Najjar type I is an exceptionally rare condition found in neonates and is characterized by severe jaundice (bilirubin &gt;20",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and neurologic impairment due to kernicterus. Crigler-Najjar type II is somewhat more common than type I. Patients live into adulthood with serum bilirubin levels that range from 6 to 25",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      Bilirubin UDP glucuronosyltransferase activity is typically present but greatly reduced. Bilirubin UDP glucuronosyltransferase activity can be induced by the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      , which can reduce serum bilirubin levels in these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=see_link\">",
"       \"Crigler-Najjar syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Conjugated hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated conjugated hyperbilirubinemia is found in two rare inherited conditions: Dubin-Johnson syndrome and Rotor syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8314?source=see_link\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with both conditions present with asymptomatic jaundice typically in the second decade of life. The defect in Dubin-Johnson syndrome is altered hepatocyte excretion of bilirubin into the bile ducts, while Rotor syndrome appears to be due to defective hepatic reuptake of bilirubin by hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dubin-Johnson syndrome and Rotor syndrome should be suspected in patients with mild hyperbilirubinemia (with a direct-reacting fraction of approximately 50 percent) in the absence of other abnormalities of standard liver biochemical tests. Normal levels of serum alkaline phosphatase and gamma-glutamyl transpeptidase help to distinguish these conditions from disorders associated with biliary obstruction. Differentiating between these syndromes is possible but clinically unnecessary due to their benign nature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ISOLATED ELEVATION OF THE ALKALINE PHOSPHATASE AND/OR GAMMA GLUTAMYL TRANSPEPTIDASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum alkaline phosphatase is derived predominantly from the liver and bones, although other sources may contribute to serum levels in some settings. Women in the third trimester of pregnancy, for example, have elevated serum alkaline phosphatase levels due to an influx into blood of placental alkaline phosphatase. Individuals with blood types O and B can have elevated serum alkaline phosphatase levels after eating a fatty meal due to an influx of intestinal alkaline phosphatase. Infants and toddlers occasionally display transient marked elevations of alkaline phosphatase in the absence of detectable bone or liver disease. There are also reports of a benign familial occurrence of elevated serum alkaline phosphatase due to intestinal alkaline phosphatase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43989?source=see_link\">",
"     \"Transient hyperphosphatasemia of infancy and early childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alkaline phosphatase levels also vary with age. Alkaline phosphatase levels are generally higher in children and adolescents because of physiological osteoblastic activity. Levels may be up to three times higher than in healthy adults, with maximum levels in infancy and adolescence, coinciding with periods of maximum bone growth velocity (",
"    <a class=\"graphic graphic_figure graphicRef56695 \" href=\"mobipreview.htm?12/30/12783\">",
"     figure 1",
"    </a>",
"    ). Also, the normal serum alkaline phosphatase level gradually increases from age 40 to 65 years, particularly in women. The normal alkaline phosphatase level for an otherwise healthy 65-year-old woman is more than 50 percent higher than for a healthy 30-year-old woman.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Determining the source of the alkaline phosphatase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation of an elevated alkaline phosphatase is to identify its source. Although electrophoretic separation on either polyacrylamide gel or Sepharose is the most sensitive and specific way to do this, these tests are not widely available. If gel electrophoresis is not available, either a GGT level or serum 5'-nucleotidase level should be obtained. These tests are usually elevated in parallel with the alkaline phosphatase in liver disorders but are not increased in bone disorders. An elevated serum alkaline phosphatase with a normal GGT or 5'-nucleotidase should prompt an evaluation for bone diseases (",
"    <a class=\"graphic graphic_algorithm graphicRef78223 \" href=\"mobipreview.htm?13/25/13727\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link&amp;anchor=H5#H5\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\", section on 'Clinical significance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link&amp;anchor=H5#H5\">",
"     \"Bone physiology and biochemical markers of bone turnover\", section on 'Markers of bone turnover'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7978?source=see_link&amp;anchor=H16031905#H16031905\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=see_link&amp;anchor=H29575819#H29575819\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\", section on 'Diagnosis and evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Initial testing for alkaline phosphatase of hepatic origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic cholestatic or infiltrative liver diseases should be considered in patients in whom an isolated alkaline phosphatase elevation is determined to be of liver origin and persists over time. The most common causes include partial bile duct obstruction, primary biliary cirrhosis (PBC), primary sclerosing cholangitis, adult bile ductopenia, and certain drugs such as androgenic steroids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . Infiltrative diseases include sarcoidosis, other granulomatous diseases, amyloidosis, and, less often, unsuspected cancer metastatic to the liver.",
"   </p>",
"   <p>",
"    Initial testing should include right upper quadrant ultrasonography (which can assess the hepatic parenchyma and bile ducts) and a test for antimitochondrial antibodies (AMA), which are highly suggestive of PBC (",
"    <a class=\"graphic graphic_algorithm graphicRef78223 \" href=\"mobipreview.htm?13/25/13727\">",
"     algorithm 1",
"    </a>",
"    ). The presence of biliary dilatation suggests obstruction of the biliary tree. In patients with biliary dilatation or choledocholithiasis, cholangiography (either magnetic resonance cholangiopancreatography [MRCP] or endoscopic retrograde cholangiopancreatography [ERCP] depending upon the clinical setting and degree of suspicion for a stone) should be done to identify the cause of obstruction and to allow for an intervention such as stone removal or stent placement. Patients with a positive AMA should have a liver biopsy to verify the diagnosis of PBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Patients in whom initial testing is unrevealing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest a liver biopsy and either an ERCP or MRCP if the AMA and ultrasonography are both negative and the serum alkaline phosphatase is persistently more than 50 percent above normal for more than six months. If the alkaline phosphatase is less than 50 percent above normal, all of the other liver biochemical tests are normal, and the patient is asymptomatic, we suggest observation alone since further testing is unlikely to influence management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Gamma glutamyl transpeptidase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma glutamyl transpeptidase is found in hepatocytes and biliary epithelial cells. In normal full-term neonates, serum GGT activity is six to seven times the upper limit of the adult reference range; levels decline and reach adult levels by 5 to 7 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/41\">",
"     41",
"    </a>",
"    ]. GGT is sensitive for detecting hepatobiliary disease, but its usefulness is limited by its lack of specificity. Elevated levels of serum GGT have been reported in a wide variety of clinical conditions, including pancreatic disease, myocardial infarction, renal failure, chronic obstructive pulmonary disease, diabetes mellitus, and alcoholism. High serum GGT values are also found in patients taking medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and barbiturates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authorities have advocated using the GGT to identify patients with occult alcohol use. The reported sensitivity of an elevated GGT for detecting alcohol ingestion has ranged from 52 to 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/22,42\">",
"     22,42",
"    </a>",
"    ]. Its lack of specificity makes its use for this purpose questionable. A population-based study found that men with increased GGT levels who also had a hyperechogenic liver by ultrasonography (suggesting the presence of steatosis) have increased all-cause mortality rates, but more data are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest GGT be used to evaluate elevations of other serum enzyme tests (eg, to confirm the liver origin of an elevated alkaline phosphatase or to support a suspicion of alcohol abuse in a patient with an elevated AST and an AST:ALT ratio of greater than 2:1). An elevated GGT with otherwise normal liver biochemical tests should not lead to an exhaustive work-up for liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     EVALUATION OF PATIENTS WITH SIMULTANEOUS ELEVATION OF SEVERAL LFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The previous sections have discussed the evaluation of isolated elevations of a single liver biochemical test. The following sections will focus upon common presentations of patients who have elevation of several of the tests simultaneously. As discussed above, it is helpful to attempt to divide this group of patients into those with a predominantly hepatocellular process and those with a predominantly cholestatic process, although the distinction is not always possible. Patients with a predominantly cholestatic pattern may be further divided into those with intra- or extrahepatic cholestasis (",
"    <a class=\"graphic graphic_table graphicRef57570 \" href=\"mobipreview.htm?37/16/38156\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The degree of aminotransferase elevation can occasionally help in differentiating between hepatocellular and cholestatic processes. While ALT and AST values less than eight times the upper limit of normal may be seen in either hepatocellular or cholestatic liver disease, values 25 times the upper limit of normal or higher are seen primarily in hepatocellular diseases. On the other hand, patients with jaundice from cirrhosis may have normal levels or only slight elevations of the aminotransferases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Predominantly hepatocellular pattern with jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common hepatocellular diseases that can cause jaundice include viral and toxic hepatitis (including drugs, herbal therapies and alcohol) and end-stage cirrhosis from any cause (",
"    <a class=\"graphic graphic_table graphicRef77337 \" href=\"mobipreview.htm?19/56/20363\">",
"     table 5",
"    </a>",
"    ). Wilson disease should be considered in young adults.",
"   </p>",
"   <p>",
"    Autoimmune hepatitis predominantly occurs in young to middle-aged women (although it may affect men and women of any age) and should particularly be considered in patients who have other autoimmune diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholic hepatitis can be differentiated from viral and toxin related hepatitis by the pattern of the serum aminotransferase levels. Patients with alcoholic hepatitis typically have an AST:ALT ratio of at least 2:1. The AST rarely exceeds 300",
"    <span class=\"nowrap\">",
"     unit/L.",
"    </span>",
"    In contrast, patients with acute viral hepatitis and toxin-related injury severe enough to produce jaundice typically have aminotransferase levels greater than 500",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    with the ALT greater than or equal to the AST.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute viral hepatitis can develop jaundice. Appropriate testing for suspected acute viral hepatitis includes a:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgM antibody to hepatitis A virus",
"     </li>",
"     <li>",
"      HBsAg",
"     </li>",
"     <li>",
"      IgM anti-HBc",
"     </li>",
"     <li>",
"      Hepatitis C viral RNA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with acute hepatitis C are usually asymptomatic. As a result, acute hepatitis C is an uncommon cause of acute viral hepatitis that is clinically evident. Nevertheless, testing for acute HCV infection is reasonable and should be performed by requesting an assay for serum hepatitis C viral RNA since hepatitis C antibody may take weeks to months to become detectable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Toxic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced hepatocellular injury can be classified as either predictable or unpredictable. Predictable drug reactions are dose-dependent and affect all patients who ingest a toxic dose of the drug in question. The classic example is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    hepatotoxicity. Unpredictable, or idiosyncratic, drug reactions are not dose dependent and occur in a minority of patients. Virtually any drug can cause an idiosyncratic reaction. As discussed above, features suggesting drug toxicity include lack of illness prior to ingesting the drug, clinical illness or biochemical abnormalities developing after the drug is begun, and improvement after the drug is withdrawn.",
"   </p>",
"   <p>",
"    Environmental toxins are also an important cause of hepatocellular injury. Examples include industrial chemicals such as vinyl chloride, herbal preparations containing pyrrolizidine alkaloids (Jamaica bush tea), and the mushrooms Amanita phalloides or verna containing highly hepatotoxic amatoxins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Shock liver (ischemic hepatitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a prolonged period of systemic hypotension (eg, following a cardiac arrest or with severe heart failure) may develop ischemic injury to several organs including the liver. Striking increases in serum aminotransferase levels (exceeding 1000 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    or 50 times the upper limit of normal) and lactic dehydrogenase may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Patients may also develop jaundice, hypoglycemia, and hepatic synthetic dysfunction. The majority of patients have concomitant deterioration of renal function. The prognosis depends mostly upon the underlying condition. Hepatic function usually returns to normal within several days of the acute episode. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18568?source=see_link\">",
"     \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Wilson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Wilson disease can occasionally present with acute and even fulminant hepatitis. The diagnosis should be considered in patients younger than 40, particularly those who have concomitant hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with autoimmune hepatitis can present with acute and even fulminant hepatitis. The diagnosis is established by the clinical setting, exclusion of other causes, serologic testing, and a liver biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Predominantly cholestatic pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in evaluating patients whose LFT pattern predominantly reflects cholestasis is to determine whether the cholestasis is due to an intra- or extrahepatic cause (",
"    <a class=\"graphic graphic_table graphicRef57570 \" href=\"mobipreview.htm?37/16/38156\">",
"     table 4",
"    </a>",
"    ). However, the distinction is not always straightforward since the history, physical examination, and laboratory tests are often not helpful.",
"   </p>",
"   <p>",
"    A reasonable first step is to obtain right upper quadrant ultrasonography, which has a number of advantages compared with other imaging modalities. It is inexpensive, does not expose the patient to ionizing radiation, and can detect dilatation of the intra- and extrahepatic biliary tree with a high degree of sensitivity and specificity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21992?source=see_link\">",
"     \"Ultrasonography of the hepatobiliary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absence of biliary dilatation suggests intrahepatic cholestasis, while the presence of biliary dilatation indicates extrahepatic cholestasis. False negative results occur in patients with partial obstruction of the bile duct or in patients with cirrhosis or primary sclerosing cholangitis where scarring prevents the intrahepatic ducts from dilating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Extrahepatic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ultrasonography may indicate extrahepatic cholestasis, it rarely identifies the site or cause of obstruction. The distal bile duct is a particularly difficult area to visualize by ultrasound because of overlying bowel gas. Appropriate next tests include CT and MRCP. CT is better than ultrasonography for assessing the head of the pancreas and for identifying choledocholithiasis in the distal bile duct, particularly when the ducts are not dilated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choledocholithiasis is the most common cause of extrahepatic cholestasis. The clinical presentation can range from mild right upper quadrant discomfort with only minimal elevations of the enzyme tests to ascending cholangitis with jaundice, sepsis, and circulatory collapse. Choledocholithiasis is usually associated with elevation of the serum alkaline phosphatase out of proportion to the aminotransferases, although elevation of aminotransferases to greater than 1000 int.",
"      <span class=\"nowrap\">",
"       unit/L",
"      </span>",
"      may be seen early in the course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/18/34090/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      MRCP is a noninvasive technique for imaging the bile and pancreatic ducts that may replace ERCP as the initial diagnostic test in cases where the need for intervention is felt to be small. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=see_link\">",
"       \"Magnetic resonance cholangiopancreatography\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      ERCP is the gold standard for identifying choledocholithiasis. It is performed by introducing a side-viewing endoscope orally into the duodenum. The ampulla of Vater is visualized and a catheter is advanced through the ampulla. Injection of dye allows for the visualization of the bile duct and the pancreatic duct. The success rate for cannulation of the bile duct ranges from 80 to 95 percent depending on the operator's experience. In addition to its diagnostic capabilities, ERCP allows for therapeutic interventions including the removal of bile duct stones and the placement of a stent.",
"      <br/>",
"      <br/>",
"      In patients in whom ERCP is unsuccessful, transhepatic cholangiography can provide the same information. Choledocholithiasis can also be detected with endoscopic ultrasonography. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43557?source=see_link\">",
"       \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignant causes of extrahepatic cholestasis include pancreatic, gallbladder, ampullary, and cholangiocarcinoma. The last is most commonly associated with PSC and is exceptionally difficult to diagnose because its appearance is often identical to that of PSC. Pancreatic, gallbladder, and cholangiocarcinoma are rarely resectable and have poor prognoses. Ampullary carcinoma has the highest surgical cure rate of all the tumors that present as painless jaundice. Hilar lymphadenopathy due to metastases from other cancers (eg, breast, colon) may cause obstruction of the extrahepatic biliary tree.",
"     </li>",
"     <li>",
"      Patients with PSC may have clinically important strictures limited to the extrahepatic biliary tree. Patients who have a dominant stricture can be managed effectively with serial endoscopic dilations and stent placement.",
"     </li>",
"     <li>",
"      Chronic pancreatitis uncommonly causes strictures of the distal common bile duct where it passes through the head of the pancreas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=see_link\">",
"       \"Complications of chronic pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AIDS cholangiopathy (usually due to infection of the bile duct epithelium with cytomegalovirus [CMV] or Cryptosporidium) has a cholangiographic appearance similar to that of PSC. Patients usually present with greatly elevated serum alkaline phosphatase levels (around 800 int.",
"      <span class=\"nowrap\">",
"       unit/L)",
"      </span>",
"      with a normal or near normal bilirubin level. Thus, these patients do not typically present with jaundice. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26069?source=see_link\">",
"       \"AIDS cholangiopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Intrahepatic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The list of possible causes of intrahepatic cholestasis is long and varied (",
"    <a class=\"graphic graphic_table graphicRef57570 \" href=\"mobipreview.htm?37/16/38156\">",
"     table 4",
"    </a>",
"    ). A number of conditions that typically cause a hepatocellular pattern of injury can also present as a cholestatic variant. As examples, hepatitis B and C can cause a cholestatic hepatitis (fibrosing cholestatic hepatitis), which has histological features that mimic large duct obstruction. This disease variant has been reported in patients who have undergone solid organ transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .) Hepatitis A, alcoholic hepatitis, EBV, and CMV can also present as cholestatic liver disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug-induced cholestasis usually is reversible after elimination of the offending drug, although it may take many months for cholestasis to resolve. Drugs most commonly associated with cholestasis are the anabolic and contraceptive steroids. Cholestatic hepatitis has also been reported with chlorpromazine, imipramine, tolbutamide, sulindac, cimetidine, erythromycin estolate, trimethoprim-sulfamethoxazole, and penicillin-based antibiotics such as ampicillin and dicloxacillin. Rarely drug-induced cholestasis may be chronic and associated with progressive fibrosis. This pattern has been described with chlorpromazine and prochlorperazine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link\">",
"       \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis is a disease predominantly of middle-aged women in which there is a progressive destruction of interlobular bile ducts. The diagnosis is made by the presence the antimitochondrial antibodies, which are found in 95 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary sclerosing cholangitis (PSC) is characterized by the destruction and fibrosis of larger bile ducts. The disease may involve only the intrahepatic ducts and present as intrahepatic cholestasis. However, in 65 percent of patients with PSC, both intra- and extrahepatic ducts are involved. The diagnosis of PSC is made by MRCP or ERCP in which the pathognomonic findings are multiple strictures of bile ducts with dilatations proximal to the strictures. A majority of patients with PSC have inflammatory bowel disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vanishing bile duct syndrome and adult bile ductopenia are rare conditions in which there are a decreased number of bile ducts seen in liver biopsy specimens. This picture is seen in patients who develop chronic graft rejection after liver transplantation, in rare cases of sarcoidosis, in patients taking certain drugs including chlorpromazine, and on an idiopathic basis. There are also familial forms of intrahepatic cholestasis. Benign recurrent cholestasis is an autosomal recessive disease marked by recurrent, self-limited episodes of jaundice and pruritus. Cholestasis of pregnancy occurs in the second and third trimesters and resolves after delivery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8314?source=see_link\">",
"       \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes of intrahepatic cholestasis include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      , non-hepatobiliary sepsis, benign post-operative cholestasis, and a paraneoplastic syndrome (Stauffer's syndrome) associated with a number of different malignancies, including renal cell carcinoma, Hodgkin lymphoma, medullary thyroid cancer, renal sarcoma, T-cell lymphoma, prostate cancer, and several gastrointestinal malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/6/23651?source=see_link\">",
"       \"Patient information: Toxic hepatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common laboratory measures classified as liver function tests (LFTs, or more appropriately liver biochemical tests) include the enzyme tests (principally the serum aminotransferases, alkaline phosphatase, and gamma glutamyl transpeptidase), tests of synthetic function (principally the serum albumin concentration and prothrombin time), and the serum bilirubin, which reflects hepatic transport capability. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complete medical history is the single most important part of the evaluation of the patient with elevated LFTs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should focus upon findings suggesting the presence of liver disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A critical step in guiding the evaluation is determining the overall pattern of the abnormal LFTs, which can be broadly divided into two categories: (1) patterns predominantly reflecting hepatocellular injury, (2) patterns predominantly reflecting cholestasis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to pursue specific testing should be guided by the pretest probability of the underlying liver disease, the pattern of abnormalities, and suggestive features obtained from the history and physical examination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Common patterns of LFT abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/1\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 2002; 123:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/2\">",
"      Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/3\">",
"      Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006; 101:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/4\">",
"      Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/5\">",
"      Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/6\">",
"      Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007; 133:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/7\">",
"      Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci 1993; 38:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/8\">",
"      Katkov WN, Friedman LS, Cody H, et al. Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. Ann Intern Med 1991; 115:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/9\">",
"      Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/10\">",
"      Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/11\">",
"      Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94:3010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/12\">",
"      Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/13\">",
"      Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/14\">",
"      Lazo M, Selvin E, Clark JM. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 2008; 148:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/15\">",
"      Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012; 55:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/16\">",
"      Ruhl CE, Everhart JE. Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. Gastroenterology 2010; 138:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/17\">",
"      Kaplan MM. Alanine aminotransferase levels: what's normal? Ann Intern Med 2002; 137:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/18\">",
"      Dutta A, Saha C, Johnson CS, Chalasani N. Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology 2009; 50:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/19\">",
"      Myers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003; 37:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/20\">",
"      Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/21\">",
"      Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/22\">",
"      Moussavian SN, Becker RC, Piepmeyer JL, et al. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease. Dig Dis Sci 1985; 30:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/23\">",
"      Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005; 41:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/24\">",
"      Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 1995; 10:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/25\">",
"      Saha B, Maity C. Alteration of serum enzymes in primary hypothyroidism. Clin Chem Lab Med 2002; 40:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/26\">",
"      Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004; 2:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/27\">",
"      Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/28\">",
"      Olsson RG, Lindgren A, Zettergren L. Liver involvement in Addison's disease. Am J Gastroenterol 1990; 85:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/29\">",
"      Boulton R, Hamilton MI, Dhillon AP, et al. Subclinical Addison's disease: a cause of persistent abnormalities in transaminase values. Gastroenterology 1995; 109:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/30\">",
"      Roblin X, Boudemaghe T, Le Gall S, et al. Use of the Synacthene test in the assessment of aminotransferase elevation. J Hepatol 2002; 36:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/31\">",
"      Miller KK, Grinspoon SK, Ciampa J, et al. Medical findings in outpatients with anorexia nervosa. Arch Intern Med 2005; 165:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/32\">",
"      Ozawa Y, Shimizu T, Shishiba Y. Elevation of serum aminotransferase as a sign of multiorgan-disorders in severely emaciated anorexia nervosa. Intern Med 1998; 37:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/33\">",
"      Di Pascoli L, Lion A, Milazzo D, Caregaro L. Acute liver damage in anorexia nervosa. Int J Eat Disord 2004; 36:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/34\">",
"      Rivera-Nieves J, Kozaiwa K, Parrish CR, et al. Marked transaminase elevation in anorexia nervosa. Dig Dis Sci 2000; 45:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/35\">",
"      Furuta S, Ozawa Y, Maejima K, et al. Anorexia nervosa with severe liver dysfunction and subsequent critical complications. Intern Med 1999; 38:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/36\">",
"      De Caprio C, Alfano A, Senatore I, et al. Severe acute liver damage in anorexia nervosa: two case reports. Nutrition 2006; 22:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/37\">",
"      Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/38\">",
"      Das A, Post AB. Should liver biopsy be done in asymptomatic patients with chronically elevated transaminases: A cost-utility analysis (abstract). Gastroenterology 1998; 114:A9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/39\">",
"      Sorbi D, McGill DB, Thistle JL, et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000; 95:3206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/40\">",
"      van de Steeg E, Str&aacute;neck&yacute; V, Hartmannov&aacute; H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/41\">",
"      Cabrera-Abreu JC, Green A. Gamma-glutamyltransferase: value of its measurement in paediatrics. Ann Clin Biochem 2002; 39:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/42\">",
"      Orrego H, Blake JE, Israel Y. Relationship between gamma-glutamyl transpeptidase and mean urinary alcohol levels in alcoholics while drinking and after alcohol withdrawal. Alcohol Clin Exp Res 1985; 9:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/43\">",
"      Haring R, Wallaschofski H, Nauck M, et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/44\">",
"      Gitlin N, Serio KM. Ischemic hepatitis: widening horizons. Am J Gastroenterol 1992; 87:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/45\">",
"      Fuchs S, Bogomolski-Yahalom V, Paltiel O, Ackerman Z. Ischemic hepatitis: clinical and laboratory observations of 34 patients. J Clin Gastroenterol 1998; 26:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/46\">",
"      Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003; 82:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/18/34090/abstract/47\">",
"      Nathwani RA, Kumar SR, Reynolds TB, Kaplowitz N. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol 2005; 100:295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3576 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34090=[""].join("\n");
var outline_f33_18_34090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H50\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMMON PATTERNS OF LFT ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MILD CHRONIC ELEVATION IN SERUM AMINOTRANSFERASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Step one",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Alcohol abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hepatic steatosis and steatohepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Step two",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Muscle disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Thyroid disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Step three",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H936652365\">",
"      - Adult bile ductopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Step four",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Whom to observe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Whom to biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ISOLATED HYPERBILIRUBINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Unconjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Hemolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Impaired hepatic uptake or conjugation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ISOLATED ELEVATION OF THE ALKALINE PHOSPHATASE AND/OR GAMMA GLUTAMYL TRANSPEPTIDASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Determining the source of the alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Initial testing for alkaline phosphatase of hepatic origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Patients in whom initial testing is unrevealing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Gamma glutamyl transpeptidase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      EVALUATION OF PATIENTS WITH SIMULTANEOUS ELEVATION OF SEVERAL LFTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Predominantly hepatocellular pattern with jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Toxic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Shock liver (ischemic hepatitis)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Predominantly cholestatic pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Extrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3576|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?13/25/13727\" title=\"algorithm 1\">",
"      Evaluation alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3576|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/30/12783\" title=\"figure 1\">",
"      Alk phos range child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3576|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/52/3915\" title=\"table 1\">",
"      Probability abnormal test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/33/27164\" title=\"table 2\">",
"      Eval isolated transaminitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/55/28541\" title=\"table 3\">",
"      Classification of jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/16/38156\" title=\"table 4\">",
"      Cholestatic causes jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/56/20363\" title=\"table 5\">",
"      Hepatocellular causes jaundice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36294?source=related_link\">",
"      Clinical aspects of serum bilirubin determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=related_link\">",
"      Crigler-Najjar syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21128?source=related_link\">",
"      Hepatic ductopenia and vanishing bile duct syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=related_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18568?source=related_link\">",
"      Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/63/21494?source=related_link\">",
"      Liver biochemical tests that detect injury to hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43989?source=related_link\">",
"      Transient hyperphosphatasemia of infancy and early childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21992?source=related_link\">",
"      Ultrasonography of the hepatobiliary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_18_34091="Feeding intolerance premature";
var content_f33_18_34091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical criteria of feeding intolerance in preterm infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abdominal examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change in bowel sounds (eg, increased or absent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Emesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastric residual volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greater than 2 mL/kg of body weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greater than half the volume of feeds over prior&nbsp;three hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any change in quantity of fluid volume (usually increase)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastric residual fluid characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Change in color",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Green: Bile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Red or brown: Blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stools",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any change in frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of blood or guaiac positive stools",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any change in clinical status",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34091=[""].join("\n");
var outline_f33_18_34091=null;
var title_f33_18_34092="Methods for diagnosing human herpesvirus 6 infections";
var content_f33_18_34092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HHV-6 diagnostic tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assay",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Culture",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Positive results represent active infection or replication",
"        </p>",
"        <p>",
"         Able to distinguish between HHV-6A and HHV-6B variants",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Technically difficult",
"        </p>",
"        <p>",
"         Long turn-around time",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        PCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        DNA PCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Plasma",
"       </td>",
"       <td>",
"        <p>",
"         Correlates well with diagnostic and clinical indicators of primary infection and with virus isolation after transplantation",
"        </p>",
"        <p>",
"         Able to distinguish between HHV-6A and HHV-6B variants",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PBMC",
"       </td>",
"       <td>",
"        <p>",
"         Able to distinguish between HHV-6A and HHV-6B variants",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Requires quantitative cut-offs for established sensitivity threshold in order to distinguish latent from active infection",
"        </p>",
"        <p>",
"         Negative results may be difficult to interpret in lymphopenic patients (eg, HCT recipients early after transplantation)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        CSF",
"       </td>",
"       <td>",
"        Able to distinguish between HHV-6A and HHV-6B variants",
"       </td>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Reverse transcription - PCR",
"       </td>",
"       <td>",
"        <p>",
"         Positive results represent active infection or replication",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Conventional",
"       </td>",
"       <td>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Does not reliably distinguish between active and latent infection",
"        </p>",
"        <p>",
"         There may be interference from maternal antibodies around the time of primary infection",
"        </p>",
"        <p>",
"         Immunocompromised patients do not reliably mount an antibody response",
"        </p>",
"        <p>",
"         Unable to distinguish between HHV-6A and HHV-6B variants",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Avidity assays",
"       </td>",
"       <td>",
"        <p>",
"         Able to distinguish between antibody associated with primary versus established infection",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unable to distinguish between reactivation and latent infection",
"        </p>",
"        <p>",
"         Unable to distinguish between HHV-6A and HHV-6B variants",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HHV-6: human herpesvirus 6; PCR: polymerase chain reaction; PBMC: peripheral blood mononuclear cells; HCT: hematopoietic cell transplantation; CSF: cerebrospinal fluid.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Danielle Zerr, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34092=[""].join("\n");
var outline_f33_18_34092=null;
var title_f33_18_34093="Outcome AS valve calcification";
var content_f33_18_34093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Outcome of asymptomatic severe aortic stenosis is related to the degree of valve calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 345px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 126 patients with asymptomatic severe aortic stenosis followed for a mean of 22 months, Kaplan-Meier analysis shows that event-free survival (death or aortic valve replacement) is related to the degree of aortic valve calcification observed on echocardiography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rosenhek R, Binder T, Porenta G, et al. N Engl J Med 2000; 343:611.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34093=[""].join("\n");
var outline_f33_18_34093=null;
var title_f33_18_34094="Spermatogenic response to gonadotropins";
var content_f33_18_34094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Spermatogenic responses to gonadotropins depending on time of onset of secondary hypogonadism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sperm counts in men with secondary hypogonadism (idiopathic hypogonadotropic hypogonadism) after treatment with human chorionic gonadotropin (hCG) for six months alone and then, in those in whom the sperm count did not reach the normal range (more than 40 million/ejaculate), for eight months with human menopausal gonadotropin (hMG). Patients with postpubertal onset responded to hCG, those with prepubertal onset generally required the addition of hMG, and those with prepubertal onset and cryptorchidism were primarily resistant to therapy (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism.&nbsp;N Engl J Med 1985; 313:651.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34094=[""].join("\n");
var outline_f33_18_34094=null;
var title_f33_18_34095="Coarctation aorta PA";
var content_f33_18_34095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain radiograph showing coarctation of the aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain frontal chest radiograph from a patient with known coarctation of the aorta demonstrates an absence of the proximal descending aortic arch shadow in the expected location (arrow), immediately superior to the left main pulmonary artery. Another plain radiographic finding, not seen in this example, includes notching of the posterior thoracic ribs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_18_34095=[""].join("\n");
var outline_f33_18_34095=null;
